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81Chapter
General Introduction
Adapted from review article “A Primer on the Immune System in the 
Pathogenesis and Treatment of Atherosclerosis”
D. Segers, H.M. Garcia-Garcia, C. Cheng, R. de Crom, R. Krams,  
J.J. Wentzel, A.F.W. van der Steen, P. W. Serruys, P.J.M. Leenen, and 
J.D. Laman.
Eurointervention, 2008; 4: 378-390
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Atherosclerosis is a chronic and often progressive disease of the wall of the arterial 
vasculature. The term atherosclerosis is derived from the Greek words “athero” 
meaning gruel or paste and “skleros” meaning stiff or hard. Atherosclerosis is 
considered a major clinical problem, which underlies most ischemic events of 
both the heart as well as the brain. It is the result of the Western lifestyle and 
can start very early in life even in persons without a strong genetic disposition 
like untreated familial hypercholesteremia1-3. From the second decade onwards, 
the disease progresses more rapidly. The clinical silence of atherosclerosis is often 
broken between the 3rd and 5th decade, when patients present with ischemic 
complaints of e.g. heart and brain. 
Despite the continuing decrease in cardiovascular disease (CVD) associated death 
over the last decade, it still is one of the main causes of death in The Netherlands, 
accounting for 30,7% of total deaths in 20074. As a result, the socio-economic 
consequences remain huge. It has been estimated that in the European Union 
annual CVD-associated costs are €169 billion, of which €105 billion are costs 
directly related to healthcare5.  
Historically, atherosclerosis was simply considered as an accumulation of lipids 
in the vascular wall. In the late 90’s, Russell Ross proposed a major revision of 
this theory6, and these days the perspective of atherosclerosis as a complicated 
lipid-driven inflammatory disease is widely accepted. Lipid metabolism and 
inflammation mutually influence each other yielding the complete spectrum of 
atherosclerotic disease progression. This is reflected in the correlation between 
future cardiovascular events and the combined values of cholesterol, as indicator 
of lipid status, and CRP, as indicator of systemic inflammatory activity7, 8. Since 
CRP levels reflect systemic inflammatory activity, this notion underscores the role 
of immunity in human atherosclerosis.
The development of atherosclerosis is strongly associated with conditions like 
hypertension, diabetes, and hypercholesterolemia and bad life style habits like 
smoking and lack of physical exercise. These so-called classical risk factors 
were identified by the Framingham Heart Study9. They induce an unbeneficial 
environment for the inner cellular lining of the arteries, the endothelial cells, which 
become dysfunctional10 and loose their barrier function, enabling the circulating 
cholesterol-containing lipoproteins to pass the endothelial layer11. The cholesterol 
starts to accumulate and it becomes trapped by binding to extracellular matrix. 
Dysfunctional endothelium also produces chemokines and adhesion molecules, 
which attract and bind leukocytes to the vascular wall respectively11, and starts the 
inflammatory process, which will be discussed later.
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Important differences in lesion morphology
Atherosclerotic plaques are not uniform in their presentation. There is a large 
gradient of lesion morphologies depending on the natural history of the lesion. 
To structure organization of lesions, a classification system has been developed by 
the American Heart Association12, 13, which has been updated14 and modified15 
recently. The classification recommended by the American Heart Association 
(AHA) organizes the lesions into 6 groups (Type I-VI) and is displayed in Figure 
1.
Figure 1. Schematic of the chronological transitions between the lesion types as recommended by 
the American Heart Association. The stroke of the arrows indicated Wthe likelihood of the transition. 
Adapted from14
Intima at highly susceptible sites of arteries Intima at moderatelysusceptible sites of arteries
VI. Surface defect, hematoma, thrombosis
VII. Calcifications predominate
VIII. Fibrous tissue changes predominate 
I. isolated macrophage foam cells
V. Fibromuscular tissue layers formed
II. Multiple foam cell layers formed
III. Isolated extracellular lipid pools formed
IV. Confluent extracellular lipid pool formed
regression of 
type I-III changes 
to normal is possible
successive type IV episodes may quickly lead to occlusion
fibrosis of type VI
adds to type V thickness
and stiffness and results
in loss of lumen
regression or change of
lipid in lesion types IV-VI
may result in lesion 
types VII-VIII
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In general, plaques may be regarded as either early or mature lesions. Early lesions 
consist of the AHA Type I-III plaques. These are always small and clinically silent, 
despite the fact that lesions size usually does not predict its composition, luminal 
obstruction or clinical relevance14. As a result, all mature lesions (AHA type IV-
VI) are capable of inducing luminal obstruction to the point of clinical symptoms 
or even a fatal event. Nevertheless, the AHA Type IV-V lesions are most often 
associated with clinical presentation. These plaques are characterized by a large 
necrotic pool of lipids and cellular debris covered by a fibrous cap consisting of 
collagen and smooth muscle cells. The amount of collagenous structures present 
in these caps is essential for its stability. When the cap thins, it becomes prone 
to rupture or erosion, which will result in intraluminal thrombosis and possible 
instant occlusion of the artery, refraining downstream tissues of oxygen supply. 
These rupture-prone lesions are often called unstable or vulnerable plaques and 
are believed to be the main cause of myocardial infarctions16.
Inflammation driven by integrated innate and adaptive immune 
mechanisms
Although our awareness of the complexity of the immune system is expanding 
continuously, the principles of immune regulation of inflammation are increasingly 
well understood. Also, since the immune system plays such a central role in 
atherosclerosis, an overview of these fundamentals is essential. The figures and 
tables cover and summarize the contents of this part, while the references include 
more comprehensive reviews and detailed studies on the different subjects.
Figure 2 outlines the generic inflammatory cascade, which appears to be 
remarkably applicable to the events observed in the arterial wall upon initiation 
and progression of atherosclerotic lesions. Central to the initiation of this cascade 
is the recognition of exogenous or (altered) endogenous molecules by cells of 
both innate and adaptive immunity. Activation of cells in both arms leads to an 
integrated response, triggering the pathogenic vascular effects characteristic of the 
disease. In the following paragraphs, we focus in particular on these early steps 
of recognition and the ensuing cellular response, and apply these to the specific 
conditions of atherosclerosis, since recent developments in this area have led to 
exciting new insights in the pathogenesis of inflammatory diseases, including 
atherosclerosis. 
Innate versus adaptive immunity
Table 1 globally compares innate with adaptive immunity. The principal difference 
between the two arms of the immune system is the nature of the cellular receptors 
involved in recognition of potentially pathogenic molecules and the triggering 
of these cells, which leads to cellular activation. Receptors of adaptive immunity, 
expressed only by T- and B-lymphocytes, are generated by recombination of 
12
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gene segments, while receptors of innate immunity are encoded as such within 
the genome, not requiring genetic recombination. Leukocytes involved in 
innate immunity such as monocytes, macrophages (Mf ), dendritic cells (DC) 
and granulocytes express a large variety of receptors recognizing molecules of 
pathogens. For example, they can express receptors for bacterial compounds 
such as lipopolysaccharide (LPS) and for viral RNA (see also Tables 2 and 3, for 
receptors and ligands, respectively). The specificity of these receptors is fixed by 
the nature of their static genetic encoding. In general, all body cells can make use 
of several innate immune mechanisms involving such receptors. However, the 
leukocytes of innate immunity are unique in the fact that they provide a mobile 
response and are specialized in expressing various host defense mechanisms upon 
triggering. As a consequence of their mobility and functional specialization, these 
	  
Figure 2. The inflammatory cascade in atherosclerosis, involving collaboration of innate and adaptive 
immunity, follows a common path way.
The inflammatory response is triggered by recognition of specific molecules by cells of innate and 
adaptive immunity that lead to their activation. The ensuing inflammatory cascade is initiated by lipid 
uptake in the vessel wall, which facilitates accumulation of leukocytes. These mobile defense forces 
attempt to neutralize and remove the initial trigger. If successful, inflammation subsides and homeo stasis 
can be restored by tissue repair. Semi-successful elimination triggers tissue remodeling, allowing partial 
funct io nality.  Adapted from79. 
13
	  Table 1. Global comparison of innate and adaptive immunity.
Cells involved in innate or adaptive immunity employ distinct receptors to recognize ligands that trigger 
cellular activation. Interaction of stimulated cells of either pathway leads to further activation and release of 
inflammatory mediators and effector molecules, which are partially specific for each response type. Since 
efficacy of the adaptive immune response depends on proliferation of antigen-specific lymphocytes, the 
kinetics of innate and adaptive responses are essentially different.
14
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cells can rapidly accumulate at affected tissue sites in case of injury or infection 
and create an effective response.
In contrast to innate immunity, adaptive immunity is exclusively restricted to 
T- and B-lymphocytes. These cells employ intricate mechanisms to rearrange 
gene building blocks, thus constructing novel receptors. Such receptors are 
cell-specific (clonotypic) and the expressing cells are subsequently selected for 
optimal recognition of an antigenic ligand and clonal expansion. The T-cell 
receptor expressed on the surface of the T lymphocyte specifically recognizes 
pathogenic or self-peptides presented by major histocompatibility (MHC) class 
II (for the CD4+ T helper cells) or MHC class I (for the CD8+ cytotoxic T-cells). 
MHC molecules are the scaffolds expressed by antigen presenting cells (APC), 
which expose peptides to lymphocytes, controlling responses in infection and 
transplantation. B-lymphocytes use their unique cell surface immunoglobulin as 
antigen-specific receptor and, after activation, secrete these as antibodies that are 
able to recognize epitopes on intact proteins.
The innate response to potentially harmful substances provides immediate 
protection (seconds to hours), while the adaptive response takes longer to 
develop (days), but has the unique properties of very high specificity and memory 
formation, with a stronger and higher affinity response upon second exposure (i.e. 
the principle of vaccination). Although the definition of adaptive versus innate 
immunity is clear-cut (yes or no genetic recombination to form receptors), these 
two arms of the immune system are completely integrated and intertwined, since 
they depend on mutual activation for an optimal response (see middle part of 
Table 1). Moreover, T and B-lymphocytes express several innate receptors in 
addition to their cell-specific antigen receptor. Upon activation by recognition 
of cognate ligands, cells of both innate and adaptive immunity produce soluble 
signaling molecules, including cytokines and chemokines (Table 1). In addition, 
they express sets of costimulatory molecules on their surface guiding cellular 
interactions and modulating the ultimate response to the initial pathogenic 
stimulus. So, although the definition of the two separate arms is clear, innate and 
adaptive immunity work coordinately and jointly. Much of this coordination and 
integration is brought about by APC, in particular Mf and DC. The cells of the 
Mf/DC lineage are specialists in immune regulation by virtue of their high level 
expression of the relevant surface molecules and the ability to migrate and thus 
convey environmental information to and from the adaptive immune system. This 
environmental information is particularly sensed by a variety of innate antigen 
receptors that have been discovered over the last years and which appear to belong 
to large families of partially unknown molecules (Table 2).
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Atherosclerosis: innate and adaptive immunity out of control?
The role of the immune system in atherosclerosis has gained acceptance in the 
last two decades because of a series of experiments performed mainly by human 
pathologists in parallel to experimental vascular biologists. Pathologists showed 
that in addition to foamy Mf, also T-cells, B-cells and DC are present in human 
atherosclerotic plaques17-20 (Figure 3).  Since MHC class-II and co-stimulatory 
molecules like CD40, CD80 and CD86 were also expressed in plaques obtained 
at autopsy21-25, important requirements for local activation of adaptive immune 
mechanisms are fulfilled. Evidence suggests that activated T-cells in both human 
and mouse plaques are of oligoclonal origin26, 27, implying selective activation 
by a limited number of antigenic epitopes. The expression of Toll-like receptors 
(TLR) in human plaques, especially in vulnerable plaques, allows the activation 
of the innate immune system not only by microbial ligands, but also by potential 
endogenous ligands such as modified LDL and heat shock proteins28, 29.
These human studies were paralleled by studies in experimental atherosclerosis 
models, in particular those focusing on chemokines and cytokines, both soluble 
mediators of inflammation. Cytokines are key players in the inflammatory 
response. They are centrally involved in orchestrating the initiation, propagation 
and regulation of the inflammatory response. Many cytokines involved in 
atherosclerosis, exerting both pro-inflammatory as well as anti-inflammatory 
effects. A summary of cytokines in atherosclerosis have been recently reviewd 
in30. Chemokines, a combination of the words chemotactic cytokines, are a family 
of proteins that play an important role in atherosclerosis31. They control the 
innate immunity receptors adaptive immunity receptors
receptors as such encoded in the genome receptors generated by genetic recombination
scavenger receptors 
(e.g. CD36, SR-A1/2, CD68, LDL-R)
toll-like receptors
NOD-like receptors 
C-type lectins 
immunoglobulin Fc receptors 
complement receptors
T cell receptors (TCR)
estimated potential repertoire: 
~1018 different R
actually present: ~107
B cell receptors (BCR/immunoglobulins)
estimated potential repertoire: 
~1011 different R
actually present: ~107
Table 2. Major receptors used in innate and adaptive immunity.  
Cells involved in innate and adaptive immune responses use essentially distinct receptors to recognize 
potentially harmful substances. Binding of foreign or endogenous ligands to such receptors may have 
very diverse effects, depending on the status of the cells involved and on the molecular pathway(s) 
connected to the respective receptors.
16
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Figure 3. Immune mechanisms in atherosclerosis projected onto a vulnerable plaque section. 
This schematic view displays selected mechanisms discussed in the general introduction, with special 
emphasis on immune modulatory therapy. The histological section displays a lumen-narrowing plaque, 
which consists of a large necrotic core covered by a thin fibrous cap. This is a typical example of a 
vulnerable plaque. In brief, monocytes and lymphocytes roll over, and adhere to the dysfunctional 
vascular endothelium, and subsequently migrate into the vascular wall. Next, monocytes will differentiate 
into dendritic cells and macrophages. Macrophage uptake of oxLDL results in the formation of foam cells, 
which form a major constituent of the growing plaque. Demise of foam cells by necrosis or apoptosis 
gives rise to a necrotic core. Activation of T-cells by macrophages and dendritic cells results in the 
differentiation of T-cells into distinct subsets that either promote inflammation (Th1, Th2, Th-IL-17) or 
limit the inflammatory process (Treg). Also, the neovascularization in the plaque and the vasa vasorum of 
the plaque is displayed, which possibly leads to intraplaque hemorrhages. Please note that the cartoon 
components are not drawn to scale with respect each other, nor to the underlying section. This plaque 
section was previously published in80. Adapted with permission from The American College of Cardiology 
Foundation.
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Mouse Model Effect on lesion size
Effect on plaque 
composition
Reference
CCR2-/- LDLr-/- Atherosclerosis ↓ Macrophages ↓
83
CCR2-/- Apoe-/- Neointima ↓ not described
84
CCR2-/- BM > Apoe3-Leiden Atherosclerosis ↓ Macrophages ↓, NS
58
CCR5-/- Apoe-/- Aortic root ↓ Mononuclear cells ↓
85
 Aorta ↓ T cells ↓
CCR5-/- Apoe-/- Neointima ↓ IL-10 expression SMC ↑
86
CCL5-/- BM > Apoe-\- Aortic root ↓ Macrophages ↓
87
Treating LDLr-/- with CCR5/
CXCR3 inhibitor TAK-779
Aortic root ↓ Macrophages ↓
88
Brachiocephalic artery ↓ T cells ↓
CX3CL1-/- Apoe-/- Brachiocephalic artery ↓ Macrophages ↓
89
 Aortic root ↔ Macrophages ↓
CX3CL1-/- Apoe-/- Proximal & thoracic aorta ↓ Macrophages ↓
39, 40
CX3CL1-/- LDLr-/- Brachiocephalic artery ↓ Macrophages ↓
89
 Aortic root ↓ Macrophages ↓
CX3CL1-/- CCR2-/- Apoe-/- Proximal aortic root ↓ Monocyte recruitment ↓
90
 Aorta ↓ Monocyte recruitment ↓
CCL2, CX3CR1 and CCR5 
inhibition
Aortic root ↓ Circulating Ly6C-lo ↓
91
CXCR3-/- Apoe-/- Abdominal aorta ↓ Regulatory T cells ↑
92
CXCR3 antagonist in  
LDLr-/-
Aortic root ↓ Macrophages & T cells ↓
93
CXCL10-/- Apoe-/- Aortic arch ↓ Macrophages ↓
CD4+ CXCR3+ T cells ↓
94
Table  3. Overview of literature regarding chemokines described in this thesis.
This table summarizes the effects of chemokine modulation and the effects on lesions size and 
composition of the chemokines that are further discussed in this thesis. For a more extended overview 
of other chemokines we refer to two recently published literature reviews36, 37. NS=not significant, 
SMC=smooth muscle cell, BM=bone marrow transplant.
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recruitment, growth and activation of leukocytes through their cognate G-protein 
coupled receptors, which are present on the endothelium or target leukocytes. 
Four chemokine subgroups have been described so far (CC, CXC, CX3 and XC), 
identified on the configuration of the first two cysteines in the protein. Some 
chemokines (like CXCL10) are known to bind to glycosaminoglycans present 
on the (endothelial) cell surface or the extracellular matrix32-35. This is important 
to generate a chemokine gradient, e.g. under arterial vascular flow conditions, 
which is essential for leukocyte recruitment and migration to target tissues. In 
Table 3, the chemokines further discussed in this thesis are summarized. The role 
of all chemokines relevant in atherosclerosis in murine models were extensively 
recently reviewed in36 and in37. Inhibition of various chemokines reduces plaque 
formation to different degrees31, 38-44. In addition, production of pro-inflammatory 
cytokines by activated immune cells has a pro-atherogenic effect, while the 
anti-inflammatory cytokine IL-10 limits atherosclerosis45-48. Inhibition of pro-
inflammatory compounds clearly mediates a reduction in atherosclerosis49-51. 
These findings on the role of the immune system in atherosclerosis have all been 
excellently and extensively reviewed recently, with emphasis on general aspects52, 
innate immunity 52-56, adaptive immunity 57 and immunomodulation 57. 
The role of innate immunity in atherosclerosis
The monocyte-macrophage lineage is considered to play a central role in innate 
immunity as well as in atherosclerosis. For example, studies in mice deficient 
for Chemokine (C-C motif ) receptor 2 (CCR2), the monocyte receptor which 
mediates transmigration into the vessel wall by MCP-1, show a reduction in 
atherosclerosis, indicating that monocyte-derived cells, presumably (activated) 
Mf aggravate atherosclerosis. Although studies in MCP-1 deficient mice further 
confirmed these early findings, recent studies indicate that the MCP1-CCR2 
axis is particularly important during early atherosclerosis and that additional 
stimuli are necessary for advanced plaque formation58. It is becoming increasingly 
clear that the monocyte-macrophage lineage is a highly heterogeneous group of 
inflammatory cells. This results in specific roles and functions attributed to highly 
specified subgroups of these cells59, and may have its consequences for their role 
in atherosclerosis. The most simplistic distinction that can be made is the division 
into classically and alternatively activated macrophages. The first will result into 
pro-inflammatory macrophages, producing matrix degrading enzymes and pro-
inflammatory cytokine, resulting in a strong inflammatory response. The second will 
mature into more resident-type macrophages, responsible for tissue homeostasis 
and repair. The (patho-)physiological role of these subsets and the relevance 
for disease are not fully understood. Nevertheless, some groups have reported 
on the relevance of these subsets of monocyte-macrophages in atherosclerosis. 
Tacke et al showed that immature Ly6Chi monocytes are dependant on different 
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chemokines to enter the lesion compared to more mature Ly6Clo monocytes60. 
This is interesting since the former is believed to mature into inflammatory 
macrophages, whereas the latter evolves into more resdident-like macrophages61, 
though the effects on atherosclerosis have not been investigated so far. 
An important way of macrophage stimulation is by TLR ligation, in particular 
TLR4 and TLR2, (reviewed in62). Lack of TLR-signaling in pro-atherogenic 
backgrounds of the mouse gives rise to decreased disease severity. In line with 
the mouse studies, some epidemiological data suggest that altered TLR function, 
caused by gene polymorphisms, protects from atherosclerosis (discussed in63). 
This might be due to changed ligation of TLR by pathogens and their derived 
products like LPS. Hence, these receptors have been mentioned as a connecting 
factor between atherosclerosis and other parameters, including circulating 
plasma endotoxins, Chlamydia pneumoniae infections and periodontal disease 
(Porphyromonas gingivalis).  Taken together, these findings suggest that the fast 
and efficient reactions against bacterial pathov gens may increase progression of 
atherosclerosis.
The importance of the innate immune system in atherosclerosis is also demonstrated 
by the ubiquitous presence in the plaques of the macrophage scavenger receptors, 
which include CD36, SR-B1, SR-A, and less known receptors such as FEEL-1, 
innate immunity ligands adaptive immunity ligands
microbial endogenous microbial endogenous
lipopolysaccharide (LPS)
lipoteichoic acid (LTA)
peptidoglycan (PGN)
PGN fragments
lipopeptides
CpG dinucleotides
double stranded RNA
single stranded RNA
flagellin
heat shock proteins 
(HSP)
HSP60
HSP70
oxLDL
fibronectin domain A
hyaluronic acid fragments
heparan sulphate
posttranslational 
modifications
potentially any 
type of microbial 
antigen present 
in the vessel wall, 
especially  HSP65 (the 
homologue to human 
HSP60)
potentially any
type of 
self-compound
HSP60
HSP65
oxLDL
Table  4. Ligands for receptors of innate and adaptive antigen receptors relevant for atherosclerosis.
Identification of ligands for innate receptors is complicated by the fact that minute amounts of contaminating 
or co-purifying compounds may be the true ligand and not the main constituent of a preparation. For 
instance, LPS preparations often contain peptidoglycan, while LPS is a notorious contaminant of many 
tools and preparations in laboratory and clinical settings. Identification of endogenous ligands for innate 
antigen receptors has been specifically plagued by this problem. For a complete overview of TLR ligands, 
see81. An overview and extensive discussion of other innate receptors and ligands is written by82.
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SR-PSOX and CD163. The scavenger receptors are low affinity receptors with 
broad ligand specificity, which play a role in the uptake of oxidized low density 
lipoprotein, oxLDL (CD36, SR-B1, SR-A and SR-PSOX) and the uptake of 
hemoglobin (CD163). They lack feedback inhibition of activity by intracellular 
cholesterol levels and as such load macrophages with oxLDL and play a key role 
in foam cell formation, one of the hallmarks of atherogenesis. 
In conclusion, the innate system is capable of rapid activation of the monocyte-
macrophage cell lineage through a variety of mechanisms, thereby contributing to 
atherosclerosis by driving proinflammatory mechanisms. This has led to a theory 
of repeated activation of innate immunity in atherogenesis by some authors 56, 64, 65.
The role of adaptive immunity in atherosclerosis
It is clear from the above-mentioned studies that the immune system plays a 
dominant role in atherogenesis. In addition to innate mechanisms, adaptive 
immunity also plays a role in atherogenesis. Important components of adaptive 
responses are expressed in plaques, including MHC class II, co-stimulatory 
molecules and Th1 cytokine profiles52, 56.  Many studies, mainly performed in 
ApoE or LDL-receptor deficient mice, show that inhibition of a specific part 
of adaptive immunity inhibits atherogenesis. Ligands relevant in the activation 
of adaptive immunity are listed in Table 4. More recently, the view has emerged 
that adaptive immunity may be particularly important in the regulation of 
plaque phenotype, i.e. stable vs. vulnerable plaque, which may rupture and lead 
to myocardial or cerebral infarction66. Vulnerable plaques display a specific 
cellular composition15, including many inflammatory cells and little stabilizing 
connective tissue. It is presently unknown how this plaque composition develops, 
but inhibition of (certain components of ) adaptive immunity has been shown to 
induce a decrease in atherosclerosis65, 67, 68. Therefore, a major conclusion from this 
research is, that the activation of adaptive immunity is associated with the severity 
of atherosclerosis (Table 5). 
As adaptive immunity needs an antigenic trigger to become activated, studies 
focused on the identification of specific antigens and epitopes involved in 
atherogenesis. Several candidates were put forward: oxLDL, Chlamydia, 
endogenous HSP60 and microbial HSP65. Especially the first candidate, oxLDL, 
is of importance as it may be regarded as a modified self-protein. Consequently, it 
has been suggested that atherosclerosis is an autoimmune disease56. Currently, the 
discussion is lively and of great importance as identification of such antigens and 
epitopes in principle allows for development of vaccines against atherosclerosis. 
Such a vaccine should induce immune responses generating protective antibodies 
or, alternatively, long-lasting immune tolerance. 
21
Animal models in atherosclerosis
Gaining detailed insight in the (molecular) mechanisms in atherosclerosis can only 
be done in animal models. It enables us to study multiple time points, interfere 
in biological pathways and perform surgical interventions on a non-therapeutical 
basis. In atherosclerosis research mice and rabbits are the most commonly 
used animals.  Generally, mice are very well protected from atherosclerosis due 
to a beneficial cholesterol spectrum in the blood. It contains high levels of the 
athero-protective HDL cholesterol and low levels of LDL and VLDL, whereas 
in humans the spectrum is opposite and pro-atherogenic.  The C57BL6 strain 
of inbred mice is relatively susceptible for atherosclerosis, since their cholesterol 
profile is less beneficial. By feeding them with an atherogenic diet, development of 
atherosclerosis can be augmented to such extend that resulting advanced lesions 
are useful to study disease mechanisms.  Over the years many variants of murine 
Table 5.  Main roles of different immune cells in the atherosclerotic plaque at distinct stages of deve-
lopment.This figure focuses on leukocytes, but other cell types are involved with atherogenesis as well.  
For instance, there is good evidence that smooth muscle cells can also develop into foam cells upon 
lipid ingestion. In addition to plaque stage, also location of leukocytes within the plaque is potentially 
important: it has been suggested that Mf producing proteolytic enzymes in the shoulder of the plaque 
codetermine plaque rupture.
plaque functions cell type
fatty streak
stable plaque
inflammation
tissue remodeling
lipid handling
antigen presentation
macrophage, foam cell
macrophage, foam cell
macrophage, foam cell
macrophage, foam cell
vulnerable plaque
inflammation
lipid handling
antigen presentation
vessel wall remodeling
transportation of antigens
 to local lymph nodes
cytokine production
cytotoxicity
growth factor secretion
inflammatory macrophage
inflammatory macrophage
inflammatory macrophage, DC
B lymphocyte
(inflammatory) macrophage
DC
B and T lymphocytes
T lymphocytes
T lymphocytes
22
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models for atherosclerosis have been proposed and widely used, most commonly 
based on two genetically engineered strains: Apolipoprotein E deficient (ApoE-
/-)69 and the LDL-receptor deficient mice70. Within each of the two variants, 
many models have been developed, e.g. based on surgical interventions, specific 
vascular locations, and also many further genetically engineered mice with either 
increased of decreased functions. Using mice has many benefits over using rabbits. 
Mice can be quickly bred, thereby offering many genetic engineering possibilities. 
Besides, the availability of histological, cellular and molecular analysis techniques 
are almost endless. Last but not least, they are cost-effective. Rabbits on the other 
hand, are especially suited for studies using (intravascular) imaging techniques, 
such as catheter based ultrasound, mainly due to their size. However, to induce 
atherosclerosis in rabbits it is necessary to inflict physical vascular damage by 
denuding the endothelial layer added to a high cholesterol diet. Also, the analytical 
and genetic possibilities are limited and costs of keeping and maintaining rabbit 
colonies are much higher than in mice.
Shear stress and atherosclerosis
Although the classical risk factors of atherosclerosis are of systemic nature, it has 
long been observed that plaques are not evenly distributed along the arterial tree. 
In fact, atherosclerotic lesions appear at specific predilection sites. These sites are 
Figure 4. Design of the shear stress modifier published by Cheng et al72
Cast model. (A; left panel) The cast consists of 2 longitudinal halves of a cylinder with a conical lumen. (B; 
right panel) The theoretical design with induction of large vortices downstream of the cast in the carotid 
artery. Additionally, the conical lumen induces a stenosis of the vessel, causing a gradual increase in 
vascular shear stress in the cast area. Because of the stenosis, a region of low shear stress is created 
upstream of the cast. 
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at or near side branches or bifurcations, where blood flow is non-uniform, or at 
the lesser curvature of bends, where blood velocity is relatively low. The effect of 
blood flow on the vessel wall is mediated through fluid shear stress, which alters 
the physiological response of endothelial cells. Shear stress in general is a force 
that is applied parallel or tangentially to the face of a material, as opposed by a 
normal force (e.g. blood pressure), which is applied perpendicular to a surface. 
Fluid shear stress arises from the friction between a fluid and the solid boundary 
along which the fluid moves, and is induced by the difference in movement of the 
two layers and the ‘roughness’ (or viscosity) between these layers. Therefore, fluid 
shear stress (from here onwards called shear stress) also arises at the interplay 
between blood (the fluid) and the endothelial layer (the solid boundary), where 
it induces a shearing deformation of the endothelial cells, which can be sensed. 
For example, when cultured endothelial cells are exposed to shear stress in vitro, 
they will display a response dependant on the shear stress pattern. High shear 
stress results in an atheroprotective response e.g. by expression of endothelial 
nitric oxide synthase (eNOS)71, 72, whereas low and oscillatory shear stress are 
pro-atherosclerotic by expression of e.g. leukocyte adhesion factors VCAM-1 
and ICAM-173, 74 and downregulation of eNOS75. The first causative evidence 
between shear stress and atherosclerosis in vivo was published by Cheng et al, 
who developed a novel method to assess the response of the vessel wall to changes 
in shear stress72. Around the common carotid artery, which is normally exposed to 
high shear stress, they placed a plastic cylinder with a gradually narrowing lumen 
(Figure 4). As a result, the vascular segment upstream of the device was now 
exposed to lowered shear stress, whereas a small part of the segment downstream 
was sensing oscillatory shear stress with reversal of flow. The segment inside 
the cylinder was exposed to high shear stress. When this method was applied 
in atherosclerosis-susceptible ApoE-/- mice, it resulted in plaque formation in 
both the upstream and downstream segments, whereas the part inside the device 
remained free of lesions76. Next, they assessed the morphology of the lesions and 
found that a plaque with characteristics of an unstable plaque had developed in the 
low shear stress segment. This lesion consisted of a large necrotic core, a thin cap 
of collagen and little smooth muscle cells. In the oscillatory shear stress segment 
on the other hand, a stable lesion had developed, containing more collagen and 
smooth muscle cells. Also, there was less matrix-degrading enzymatic activity 
compared to the low shear stress lesion.
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Aim and outline of this thesis
As mentioned before, the morphological qualities of an atherosclerotic plaque 
lay at the basis of (future) clinical consequences. Lesions with a vulnerable 
composition are prone to rupture, resulting in thrombosis and subsequent 
vascular occlusion. There is strong evidence that the shear forces of flowing 
blood inflicting on the endothelial cells influence the development of plaque 
vulnerability. However, the (immunological) mechanisms involved in this shear 
stress mediated vulnerable plaque development are currently unclear. In this thesis 
we aimed to clarify some of the immunological mechanisms involved, working 
towards future therapeutic interventions in treatment and prevention of unstable 
plaque rupture. Since it is very difficult to perform such mechanistic studies in 
humans, we studied experimental atherosclerosis in two specific animal models. 
It has been shown in humans that plaque ruptures are not equally distributed 
along the length of a lesion, but that ruptures occur more often in the upstream 
part of an atherosclerotic lesion77, 78. In chapter 2, we describe a novel technique 
in rabbits to assess the spatial distribution of the main lesion components in a 
3-dimensional fashion, explaining the upstream localization of plaque ruptures. 
In chapter 3 we tested the hypothesis that activated macrophages are the prime 
source of matrix-degrading proteases and that smooth muscle cells are the main 
producers of collagen in a shear stress driven model of murine atherosclerosis. In 
chapter 4 we evaluated the differences in chemokine expression patterns between 
the stable and unstable lesions in the shear stress driven murine model. In chapter 
5, we describe the effects of specific inhibition of CXCL10 on the plaque stability 
in atherosclerosis-susceptible mice. CXCL10 is one of the chemokines that was 
indentified to be specifically upregulated in the segment developing into the 
unstable lesion in chapter 4. In this chapter we also report on the association 
between human carotid artery lesion phenotype and its concentration of plaque 
CXCL10. 
In chapter 6 we report on the current work and (preliminary) results of a whole-
genome expression analysis of plaque tissue, comparing tissue from the low and 
oscillatory shear stress segments during the development of the two different 
plaque phenotypes.
Finally the obtained results are summarized and discussed in chapter 7 of this 
thesis.
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Abstract
Background 
Atherosclerosis is considered an inflammatory disease. Recent studies 
provided evidence for a predominant upstream location of plaque inflam-
mation. The present study introduces a novel technique that evaluates the 
underlying mechanism of this spatial organization.
Methods and Results 
In hypercholesteremic rabbits, atherosclerosis of the infra-renal aorta 
was induced by a combination of endothelial denudation and a high 
cholesterol diet (2% cholesterol; 2 months).  At sacrifice, aortic vessel 
segments were dissected and reconstructed with a new technique, which 
preserved the original intravascular ultrasound derived lumen geometry. 
This enabled us to study the spatial relation of histological markers, like 
macrophages (MF), smooth muscle cells (SMC), lipids, gelatinolytic ac-
tivity and oxidized LDL (oxLDL). Results show a predominant upstream 
localization of macrophages and gelatinase activity. Co-localization stu-
dies indicated that gelatinase activity was associated with MF and SMC. 
Further analysis revealed that this was caused by subsets of SMC and 
MF which were associated with oxLDL accumulation.
Conclusion 
Upstream localization of a vulnerable plaque phenotype is probably due 
to an accumulation of oxLDL, which activates/induces subsets of SMC 
and MF to gelatinase production.
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Introduction
Atherosclerosis is nowadays considered a lipid driven inflammatory disease. 
Inflammation has been associated with plaque progression, plaque rupture, 
thrombosis and subsequent myocardial infarction1-4. Several studies indicated 
that plaque inflammation is unevenly distributed over its length, with a 
predominant upstream presence of inflammatory cells and/or a location in the 
plaque shoulders3,5-9. These observations indicate a spatially oriented mechanism, 
which to date has not received much attention. In order to study the underlying 
mechanism of such a highly spatially localizing mechanism, there is a need for 
a precise, quantitative technique, enabling the study of plaque heterogeneity in 
experimental atherosclerosis. The first aim of the present study is to present a 
3D histological technique permitting the study of plaque heterogeneity in more 
detail as before.
Both plaque progression and plaque rupture have been associated with a 
larger infiltration of macrophages (MF), irrespective of the underlying plaque 
morphology10,11. Activated MF produce numerous factors, including matrix-
metalloproteinases (MMP)12. MMP belong to a family of zinc activated proteases 
modulating the extracellular matrix in the vascular wall13-15. The activity of some 
family members induces weak spots in the extracellular matrix, thereby introducing 
a condition sensitive to plaque rupture12,16-18. However, only a relatively small 
fraction of MF can be measured in the entire plaque19 and therefore the process of 
plaque weakening may either be very localized, or other cell types may be involved 
in the process. Indeed, several studies have indicated that, besides MF, endothelial 
cells and smooth muscle cells (SMC) may produce MMP when brought into an 
inflammatory, atherogenic environment20-22. Recently, a new technique has been 
introduced to measure gelatinolytic activity in histological cross sections with a 
high spatial resolution23,24. We have adopted this method for vascular tissue and 
incorporated it into the 3D histological reconstructions. Our second aim was to 
evaluate whether MMP are active either very locally or that multiple cell types are 
involved in experimental atherosclerosis in vivo, by combining above techniques.
Low-density lipoproteins (LDL) accumulate in the vessel wall, where they may 
become oxidized (oxLDL). OxLDL is known to be involved in many processes 
related to atherosclerosis, including stimulation of macrophage infiltration and 
foam cell formation, stimulation of vascular smooth muscle cell migration and 
proliferation, and endothelial cell apoptosis25-29. Recent studies indicated that 
oxLDL is associated with plaque instability29. This observation might be explained 
by the modulation of activation of some MMP family members by oxLDL15. 
However, most of the oxLDL related studies have been conducted on isolated 
cells in vitro, which are devoid of the complex environment of the atherosclerotic 
vessel wall, thereby identifying the need to study the role of oxLDL in vivo.  It 
is presently unknown whether oxLDL is distributed heterogeneously within the 
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plaque or if it is associated locally with Gelatinolytic activity in plaques in vivo. 
Therefore, the third aim of the present study was to evaluate if oxLDL might be 
the cause of the spatially restricted accumulation of activated MF in plaques in 
vivo.
Methods
Instrumentation
Three days before baseline measurements, male New Zealand White rabbits (n=8; 
weight=3.6±0.2 kg; Harlan, The Netherlands) were fed a high (2%) cholesterol 
diet for a 2-month period. At experimentation, rabbits were anaesthetized 
with an intramuscular injection of ketamine (Sanaket 10%, 25 mg/kg, Anisane 
BV, Raamsdonkveer, Holland) and a subcutaneous injection of medetomidine 
(Domitor, 0,5 mg/kg, Orion, Espoo, Finland). The marginal ear artery was 
canulated for arterial pressure measurement with a fluid-filled catheter (Amatek 
U.S. Gauge, Feasterville, USA) and for arterial blood withdrawal. A 4 French (Fr) 
guiding catheter was advanced from the left femoral artery up to the level of the 
renal artery ostium. Following angiography, a 40 MHz intravascular ultrasound 
(IVUS) catheter (CVUS, Boston Scientific, Maastricht, The Netherlands) was 
advanced through the guiding catheter and located 1 cm upstream of the lower 
of the two renal arteries. Subsequently, a motorized pull back was performed at a 
speed of 0.5 mm/sec spanning an arterial segment of 7 cm, which was recorded 
on high-resolution videotapes. Endothelial denudation was performed within 
this predefined segment by twisting and pulling back an inflated 3 Fr Fogarty 
balloon (Applied Cardiac Systems, Inc. Laguna Hills, USA) over a length of 5 
centimeters. 
Follow-up
After 8 weeks of follow-up, rabbits were anesthetized as described above. Next, 
the right femoral artery was dissected for the introduction of a 4 Fr sheath. An 
angiographic overview of the infra-renal aorta was performed and radiopaque 
markers were located subcutaneously to indicate the previously denuded region. 
Subsequently, the IVUS pullback was repeated at the location of the previously 
denuded segment. Following, the abdomen was opened and a longitudinal marker 
and two transverse markers were placed externally on aortic vessel wall, the lumen 
was filled with OCT compound (Tissue-Tek, Sakura Finetek Inc. Torrance, USA) 
and the arterial segment of interest was dissected, collected and snap-frozen in 
liquid nitrogen. The distance between both transverse markers was measured 
before and after excision and used to calculate a correction factor for shrinkage 
due to arterial elasticity. 
All experiments were performed in accordance with institutional regulations and 
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the “Guiding for the care and use of laboratory animals” published by the US as 
approved by the Council of the American Physiological Society.
Plasma lipids
Lipid profiles were measured according to well-established enzymatic calorimetric 
methods (Roche Diagnostics, Pleasanton, USA). Cholesterol levels were 
determined at 8 weeks follow-up in the present hypercholesteremic group and 
in a normocholesteremic control group, which consisted of sex and age-matched 
rabbits. 
 
Intravascular ultrasound 
The high-resolution videotaped IVUS data were digitized at intervals of 0.5 mm 
with a resolution of 800 x 600 pixels and stored on a standard PC. Next, the 
lumen and the acoustic interface between media and the adventitial layer were 
traced semi-automatically by a well-validated software package30, following the 
lumen area and media bounded area were calculated from these contours. The 
difference between these two was defined as the wall area.
Tissue harvesting and histological analysis
From the excised 5 cm aortic segment, tissue blocks were prepared every 2 mm 
with an in-house developed cutting device. This resulted in approximately 20-25 
blocks per blood vessel, depending on shrinkage extend. Immunohistochemistry 
was performed on 5 mm cryosections obtained from the middle of the 2 mm 
tissue blocks. Sections were stained for MF (RAM-11, Dako Diagnostics BV, 
Glostrup, DK), smooth muscle cells (a-actin, Dako Diagnostics BV, Glostrup, 
DK) and for oxidized LDL (epitope against ApoB100; 31) and lipids (Oil Red O; 
Sigma, Rotterdam, The Netherlands). Following staining, sections were digitized 
using a high-resolution CCD camera (Zeiss Axiocam HR, Jena, Germany) 
and quantitatively analyzed using commercial image analysis software (Clemex 
Technologies Inc, Longueuil, Canada).
In situ zymography
Gelatinolytic activity was demonstrated in unfixed cryosections using DQ-gelatin 
as a substrate (EnzChek; Molecular Probes, Eugene, OR). Sections were air-dried 
for 60 min, while during that period DQ-gelatin was dissolved in a concentration 
of 1 mg/ml in Milli-Q and then diluted 1:10 in 1% (w/v) low gelling temperature 
agarose (Sigma, Rotterdam, The Netherlands) in PBS. Subsequently, 25 µl of this 
mixture was placed on each cryosection and incubated for two hours at room 
temperature following placement of a cover slip. Fluorescence was detected with 
a confocal microscope (Zeiss, LSM 510 Meta, Jena, Germany) using an argon 
laser for excitation at 488 nm and emission collection at 512–542 nm, applying 
appropriate filters, background and autofluorescence correction. A detailed 
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testing for specificity of the in situ zymography was described in literature23 and 
is described in the supplemental data section as well.
3D histology
The 3D reconstruction of histological cross sections consisted of the following 
steps: i) acquisition of quantitative image analysis data from histological sections, 
ii) rotation of sections on basis of an externally placed longitudinal marker, which 
was still present following histological processing, iii) stacking of image data, 
correction for shrinkage in longitudinal and radial direction and iv) rotation of 
the entire stack of data with respect to the renal artery and mapping of histology 
on 3D IVUS reconstructions. Details of the 3D reconstruction, including several 
tests are described in the supplemental data.
Data analysis and statistics
As a first approach, we averaged each histological variable (plaque area, MF, 
SMC, lipids, Gelatinolytic activity and oxLDL) per cross section and displayed 
the longitudinal heterogeneity per blood vessel. Subsequently, plaque areas of 
each blood vessel were shifted such that maximal plaque areas of all vessels were 
aligned. The shift for each individual blood vessel was applied to all its histological 
variables, which were eventually spatially averaged. To study spatial differences in 
relation of the histological variables described above in relation to plaque area, 
spatial averages were calculated upstream and downstream of the maximum 
plaque area for each individual animal. Differences between these averages were 
then evaluated by an exact Wilcoxon signed ranks test. 
To further explore underlying mechanisms, we performed co-localization studies 
of the reordered data as well as linear regression analyses. Co-localization was 
defined as the existence of two variables in the same radial segment. The numbers 
of co-localized pixels were counted per histological variable and divided by the 
number of total elements in the segment of interest. Differences between co-
localization of MF-gelatinolytic activity and SMC-gelatinolytic activity and of 
MF-oxLDL and SMC-oxLDL were tested.  In addition, the amount of MF as 
a fraction of total MF, and SMC as a fraction of total SMC were calculated and 
differences in co-localization were tested, as described above. Detailed explanation 
of the image segmentation is described in the data supplement.
The authors of this article had full access to all of the data in the study and take 
responsibility for the integrity of the data and the accuracy of the data analysis.
Results
Animal characteristics
Systolic, diastolic and mean arterial blood pressures were 88±1 mmHg, 60±3 
mmHg, and 69±1 mmHg, respectively. These values remained unchanged during 
the experimental procedures. The 2% cholesterol rich diet significantly increased 
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total plasma cholesterol (from 1.4±0.2 mM to 33.4±15.7 mM); HDL (from 
0.7±0.1 mM to 14.5±2.7 mM) and LDL (from 0.2±0.1 to 30.9±10.8 mM). 
Triglyceride levels remained unchanged. 
Longitudinal plaque heterogeneity displays an upstream location of 
inflammatory cells, Gelatinolytic activity and a vulnerable phenotype.
In plaques generated in the aorta of a representative hypercholesteremic rabbit, 
longitudinal plaque heterogeneity of lipid particles, MF and SMC was clearly 
present (Figure 1). Surprisingly, a similar upstream accumulation of gelatinolytic 
activity and oxLDL were measured (Figure 2). When the data were shifted 
and spatially averaged (see above) the predominant accumulation of MF was 
demonstrated for all animals (Figure 3). Distribution of each variable with plaque 
area, revealed a higher accumulation of MF upstream (11.6%) of the plaque, as 
compared to downstream of the plaque (7.9% p=0.016). In contrast, a more diffuse 
distribution of vascular SMC (26.6% vs 27.1%) and lipids (2.9% vs. 2.5%) was 
measured. As a consequence, a local vulnerability index (modified from Shiomi 
et al32) displayed a maximum upstream of maximal plaque area as compared to 
downstream (3.2 versus 2.8, p=0.039, Figure 4) This higher vulnerability upstream 
is similar to observations in the carotid arteries of patients7. 
In vivo gelatinolytic activity is co-localized with both smooth muscle 
cells and macrophages
Inspection of histological cross sections revealed that both SMC and MF were 
associated with gelatinolytic-activity (Figure 5). Quantitative analysis confirmed 
these findings, as the total amount of gelatinolytic associated with SMC and MF 
was 85±10%, distributed into an equal SMC - gelatinolytic fraction of 42±7% and 
MF - gelatinolytic fraction of 43±9% (Figure 6). While this pointed to a similar 
contribution of SMC and MF to overall gelatinolytic activity, these fractions 
represents only a minor fraction of overall MF (23±7%) and SMC (22±7%) 
content, which was similar for both cell types. When we re-examined the cross 
section containing gelatinolytic producing vascular SMC and MF, we identified 
foamy SMC and foamy MF (Figure 5; right panels).
OxLDL identifies subsets of gelatinolytic producing smooth muscle 
cells and macrophages
Inspection of histological cross sections revealed that both SMC and MF were 
associated with oxLDL accumulation (Figure 5). These single observations were 
confirmed by quantitative analysis, as co-localization of MF and SMC with 
oxLDL was 98±10%, with a contribution of 54±9% of SMC co-localizing with 
oxLDL and 44±7% of MF with oxLDL that was not different (Figure 6). These 
co-localization studies identified similar subset of SMC (28±4%) and a subset of 
MF (28±8%) that were spatially associated with oxLDL. 
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Left page top panel
Figure 1. 
3D vascular lumen reconstructions of a rabbit aorta, which was obtained by combining Intravascular 
Ultrasound (IVUS) with histological data. The upper panel shows the histology projected on the 3D IVUS 
lumen reconstruction, while the bottom panel shows the same data on a flat plane. From left to right are 
displayed: lipid distribution, macrophage distribution, smooth muscle cell distribution, and IVUS derived 
wall thickness distribution. Flow direction is from the bottom to the top. Note the predominant upstream 
location of inflammatory markers.  
Left page bottom panel
Figure 2. 
3D reconstructions of the same aorta as presented in figure 1. Presented are histological markers 
projected on a flat plane only. From left to right are displayed: oxidized LDL distribution, macrophage 
distribution, the distribution of metalloproteinase gelatinolytic activity, and smooth muscle cell distribution. 
Flow direction is from the bottom to the top. Note the predominant upstream location of all components, 
similar as presented in figure 1.  
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Figure 3. 
Longitudinal heterogeneity of plaque area (panel A), macrophage (panel B), smooth muscle cell (panel 
C) and lipid distribution (panel D).  Displayed in each figure is the longitudinal plaque area distribution as 
averaged for all rabbits, note that all variables are located predominantly upstream of the plaque. 
Figure 4. 
Local distribution of the vulnerability index adapted from Shiomi32, displayed as a function of longitudinal 
location in a series of atherosclerotic rabbit aortas (n=10). A high value signifies a more vulnerable 
phenotype, while a low value signifies a more stable phenotype. It is clearly shown that the highest values 
are displayed upstream of the plaque.
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Discussion
Atherosclerosis is considered a lipid driven inflammatory disease. Several studies 
indicated a strong heterogeneity of the inflammatory process11,33,34, consisting 
either of an accumulation of inflammatory cells in the shoulders and/or upstream 
of the plaque7. Not much attention has been paid to this heterogeneity in 
experimental atherosclerosis, probably due to the lack of a suitable technique to 
study such phenomena in animals. 
With a new 3D reconstruction technique for histology, we were able to show that 
the inflammatory component in the atherosclerotic plaque was spatially located 
upstream of the maximal cross-sectional plaque area, similar as reported for 
human conditions7. In addition, we demonstrated that gelatinolytic activities were 
also spatially confined to the same region and were associated with MF and SMC. 
This tight spatial localization of gelatinases enabled us to study co-localization 
with other cell types. We found that, not only MF, but also SMC contributed 
significantly to gelatinolytic activity in vivo. Previous studies indicated that SMC 
in culture produce pro-MMP-2 after stimulation, and at the same time reduce 
their TIMP production leading to a higher MMP-2 activity35. Furthermore, 
macrophages stimulated with oxLDL decrease their TIMP-1 release and increase 
pro-MMP-9 release, leading to MMP-9 activation22. The imbalance between 
TIMP and pro-MMP release may explain the high gelatinase activity found in 
the present study. Thus, from the present findings, one may postulate that local 
weak spots in the extracellular matrix occur upstream of the plaque because of a 
highly localized gelatinolytic concentration produced by a both (foamy) MF’s and 
(foamy) SMC. 
The reason why such a localized accumulation of cells in atherosclerotic plaques 
occurs is presently unknown, but several lines of evidence indicate that oxLDL is 
involved. OxLDL has been measured in (vulnerable) plaques, where it modulates 
macrophage accumulation and foam cell formation through the expression of 
adhesion factors and MCP-1 secretion, migration of SMC and apoptosis of SMC 
and endothelial cells27-29,36 Furthermore, several studies identified a modulating 
effect of oxLDL on MMP activation by MF and SMC in vitro37-41.  Therefore 
we tested whether oxLDL co-localized with MF and SMC. Only 25% of either 
cell type were associated with oxLDL, but these two cell types accounted for all 
oxLDL co-localization and all gelatinolytic-activity in our plaques. This indicates 
that the total oxLDL is taken up by SMC and MF in approximately similar 
amounts, but this uptake is performed by subsets of both cell types. 
Highly evolutionary preserved subsets of monocytes have been identified in 
the blood of humans and mice42,43, which results in a different macrophage 
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Figure 5. 
Near consecutive cross sections of a single atherosclerotic rabbit aorta at low magnification showing 
macrophage accumulation (panel A), gelatinolytic activity (panel B, the dashed white line indicates the 
tunica media) and smooth muscle cell distribution (panel C). Note that near the cap the gelatinolytic 
activity is high. At this location both smooth muscle cells and macrophages are identified. A 100 X 
magnification of near consecutive cross sections indicates that foam cells (Oil Red O staining; panel E) 
belong to the macrophage fraction (RAM-11; panel D) and to the smooth muscle cell fraction (a-actin: 
panel F). The dashed black lines indicate an area where foamy smooth muscle cells are present.
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phenotypes as maturation occurs 43,44. These circulating subsets express different 
chemokine receptors 43,45 and different scavenger receptors 43,44. These studies may 
offer an explanation for the finding of a subset of MF with a preferential location 
upstream of the plaque combined with a particular predominance to foam cell 
differentiation. 
Subsets of SMC may change into foam cells and therefore their role in atherogenesis 
may have been underestimated46,47. Recently, it was demonstrated that discrete 
clones of SMC exist in human vessels, which differentially accumulate cholesteryl 
esters when exposed to oxidized lipoproteins 47,48. Once turned into foamy SMC, 
they start to produce cytokines and express chemokine receptors 49 providing an 
explanation for their tight co-localization within the plaque. The fact that foamy 
SMC and foamy MF are located in similar vessel segments might be explained 
by the evidence that MF secrete factors enhancing uptake of cholesteryl ester 
by vascular SMC50. The association of foamy SMC subsets, foamy macrophage 
subsets and gelatinolytic activity in atherosclerotic plaques in vivo has, to the best 
of our knowledge not been described before.
In conclusion, a specific spatial co-localization of MF, lipids and SMC was 
demonstrated upstream of the plaque, similar as found in patients with proven 
upstream plaque ruptures. This upstream plaque composition is characterized by 
an accumulation of (subsets of ) MF and SMC, oxLDL and gelatinolytic activity. 
We hypothesize that activation of these subsets by oxLDL induces gelatinolytic 
activity, followed by breakdown of the extracellular matrix and subsequent 
weakening of the plaque. The unexpected important role of a subset of SMC in 
this process warrants further studies.
Figure 6. 
Pie diagrams of gelatinolytic activity (left panel) and oxLDL accumulation distribution, with respect 
to smooth muscle cells and macrophages. The distribution is calculated as a percentage of SMC or 
macrophages co-localized with gelatinase activity or oxLDL, divided by total gelatinolytic or total oxLDL, 
respectively. Unknown refers to the amount of either gelatinolytic activity or to the oxLDL accumulation 
not associated with either smooth muscle cells or macrophages. oxLDL: oxidized LDL.
Gelatinolytic activity oxLDL accumulation
macrophages macrophages
unknown unknown
smooth muscle 
cells
smooth muscle 
cells
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3Chapter
Atherosclerotic Plaque Vulnerability in a Mouse 
Model of Atherosclerosis is Predominantly 
Located in the Upstream Segment of the Lesion
D. Segers, R.Krams,  R. de Crom, P.J.M. Leenen.
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Abstract
Background
We previously developed a mouse model for vulnerable atherosclerotic plaque 
induced by a low shear stress pattern. In the present study we characteri-
zed various vulnerability-determining factors in this model, addressing the 
question how these factors compared to the well-described features of human 
vulnerable plaque.
Methods and Results
In ApoE-/- mice, we induced unstable plaque using a flow-altering device 
around the carotid artery for 9 weeks. Lesion compositions were evaluated 
in two equally sized plaque segments. We found frequent disruptions of the 
plaque, but only in the upstream segment. This was accompanied by increased 
macrophage activation compared to the downstream segment  (MHC class II 
staining; 15.3% vs. 6.9%, p<0.01). Collagen presence tended to be lower up-
stream, whereas production in this segment was higher. Surprisingly, colla-
gen-degrading gelatinase activity was highest in the downstream segment.
Conclusion
In the present study we show that plaque disruptions are frequent in the low 
shear stress-induced plaque and the colocalization with activated macropha-
ges suggests that they might be important in this respect. The upstream loca-
lization of disruptions is in accordance with findings in humans. We believe 
that, when the limitations of this model are respected, it may prove valuable 
for pathogenic and pre-clinical studies of unstable atherosclerosis and that 
results can be interpreted as relevant for human disease.
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Introduction
Rupture of atherosclerotic plaques is a relatively common occurrence causing 
significant morbidity and mortality. Vulnerability to rupture is associated with 
specific morphological presentation of lesions(1, 2). These plaques display a large 
core of lipid deposits and necrotic cell debris, which is covered by a thin cap of 
fibrous material, mainly collagen. The production of matrix-degrading enzymes 
like matrix metalloproteinases (MMP) by especially macrophages, results in the 
loss of collagen and subsequent thinning of the cap(3). Once the cap can no longer 
withstand the forces imposed upon it, the cap may rupture, exposing the plaque 
content to the blood. This leads to a strong coagulation response and subsequent 
formation of a thrombus, which may instantly occlude the artery at the rupture 
site and refrain the downstream tissues from oxygen supply or embolize and 
occlude vessels further downstream with similar consequences.
Recently, we developed a mouse model in which the histological characteristics of 
unstable atherosclerosis are mimicked(4). This model was based on the induction 
of different profiles of shear stress, i.e. the parallel force applied upon the 
endothelial cell layer by the flowing blood, in a straight arterial segment in ApoE 
knockout mice(5). Thus, we could provide convincing experimental evidence for 
the long-suggested concept that arterial segments exposed to low shear stress 
(LSS) or oscillatory shear stress (OSS) are more susceptible to atherosclerosis. 
These assumptions were based on the observation that inner curvatures of large 
arteries (LSS pattern) and near side branches and arterial bifurcations (OSS 
pattern) are predilection sites of atherosclerotic plaque development, reviewed 
in(6). Furthermore, we observed in this model that LSS-induced atherosclerotic 
plaques developed an unstable phenotype, in contrast to the OSS-induced 
plaques(4). This difference in plaque composition appeared to be causally related 
to the differential production of chemokines(7). In particular, fractalkine is 
produced to a larger extend in the LSS-induced plaque.
In humans, a large amount of clinical evidence has indicated that the unstable 
regions and rupture sites are predominantly located in the proximal segment of 
the plaque(8, 9). Since we now have a model available mimicking the morphology 
of an unstable human plaque, we aimed to take the analysis a step further and 
to determine how the instability is distributed over the lesion in this model. 
Therefore, we characterized various vulnerability-determining factors in low shear 
stress-induced atherosclerotic plaque, which allowed us to compare these to the 
well-described features of human plaque.
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Materials and Methods
Animals and surgical procedures
Apolipoprotein-E deficient mice (female, 15-20 weeks of age, n=13) were 
obtained from the Jackson Laboratories (Bar Harbor, ME, USA), and fed a high 
fat, high cholesterol diet consisting of 15% (wt/wt) cocoa butter and 0.25% (wt/
wt) cholesterol (Diet W, Hope Farms, Woerden, The Netherlands). Two weeks 
after this diet was initiated, the mice were anesthetized with 2% isoflurane and 
instrumented with a shear stress-altering device around the right common carotid 
artery, as described previously(4). Briefly, this device gradually narrows the vessel 
lumen to ~70% of its original diameter. As a consequence, shear stress is lowered 
upstream (low shear stress, LSS) of the device, then gradually increases inside the 
device and is oscillating (oscillatory shear stress, OSS) just downstream of the 
device(5). Mice were kept on the high fat, high cholesterol diet for the remainder 
of the experiment. The device remained in situ until sacrifice after 9 weeks. 
All animal experiments were approved by the institutional animal ethical committee 
and performed in compliance with institutional and national guidelines.
Tissue preparation, staining and analysis
Following sacrifice, mice were perfused systemically with PBS. Next, the common 
carotid artery was isolated, embedded in OCT compound (Tissue-Tek, Sakura, 
Japan), and snap-frozen in isopropanol on dry ice. For histology, 8 µm serial 
cryosections were cut covering the entire length of the lesion and stained for 
general plaque morphology (hematoxilin-eosin), lipids (Oil Red O), collagen 
(Picrosirius Red), macrophages (anti-CD68, AbD-Serotec, Oxford, UK), 
macrophage activation (anti-Major Histocompatibility Complex (MHC) class 
II, clone M5/114, ATCC TIB-120), smooth muscle cells (anti-SMC α-actin, 
Sigma-Aldrich, The Netherlands) and collagen production (anti-HSP-47, MBL 
International, Woburn, MA, USA). Following staining, high-resolution images 
ware obtained using an Olympus BX-40 microscope or a Zeiss LSM5 Meta 
confocal microscope (Zeiss Jena, Germany). Collagen stainings were assessed 
using crossed circular polarization filters. 
For in situ zymography a PBS solution of DQ™ gelatin (1 mg/ml) (Invitrogen, 
Paisley, UK) in 1% agarose (Sigma Chemical Co., Zwijndrecht, The Netherlands) 
was applied to the slides and incubated for 2 hours at room temperature. 
Gelatinase activity was detected following incubation by assessing the fluorescent 
signal using confocal microscopy. 
To calculate lesion size and cellular content relative to the plaque area all images 
were analyzed after digitalization by automated image analysis software (Clemex 
Technologies Inc, Canada) applying thresholding of the stained areas as before(4). 
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Statistical analysis
Prism 5 (GraphPad Software, La Jolla, Ca, USA) was used for all statistical ana-
lyses. Histological data of the LSS-induced plaque were divided into two equally 
sized segments, representing the upstream and downstream part of the plaque, 
respectively (Figure 1). These two segments were compared to each other. For 
each staining an average was calculated per segment, which was then used in 
the analysis. Each average resulted from approximately 5 equally spread sections. 
Differences between segments were tested by a paired t-test when data met the 
normality assumptions. If not, a nonparametric Wilcoxon matched-pairs test 
was used. Correlation analysis was performed by the Spearman nonparametric 
correlation test. Data are presented as mean ± SEM. A p-value of <0.05 was 
considered statistically significant.
Figure 1. Disruptions of atherosclerotic plaque induced by low shear stress are located in the upstream 
part of the lesion. 
Displayed are serial sections of representative H&E-stained plaque from a single mouse. Lesions 
disruptions can be identified by the pink-reddish color inside the plaque, which indicates the presence 
of erythrocytes/blood. The white lines on the sections mark the location of the lumen, which collapsed 
during dissection due to the elasticity of the artery wall and the loss of pressure at the luminal side. The 
cartoon below shows a graphical representation of the model used, and the approximated location of 
the sections above indicated by the dashed arrows. 
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Results
By systematic analysis of various vulnerability-associated factors on serial cross-
sections of LSS-induced plaques, we aimed to clarify the distribution of these 
factors over the length of the plaque and their relevance for plaque instability.
Upstream parts of the LSS plaque show evidence of plaque 
disruption
In 53% (7/13) of the mice evaluated in this study we found evidence of plaque 
disruption. This ranged from a minor amount of erythrocytes (15%), to large 
hemorrhages (15%). In 3 cases (23%) we found major newly formed canals. These 
were filled with blood, even after systemically and extensively flushing the animals 
during sacrifice, indicating that they were not continuous with the vascular lumen. 
These canals appeared to arise from the upstream part of the plaque and on average 
extended to approximately two third of the plaque’s longitudinal length (Figure 
1). All three types of disruption, i.e. erythrocyte deposits, large hemorrhages and 
canal formation, were found in the area close to the tunica media and sometimes 
in the middle part of the plaque, but never directly adjacent to the collagenous cap. 
Longitudinally, disruptions were located in the upstream segment. Importantly, 
we never observed any signs of plaque disruption in the OSS plaque segment.
Macrophages are equally distributed in the low shear stress-induced 
lesion, but are highly immune-activated in the upstream location
Macrophages are the hallmark leukocytes in atherosclerotic plaques and are 
considered to be prime cells in plaque dynamics and therefore important for 
the findings above. We compared the relative occurrence of macrophages in the 
upstream and downstream parts the LSS plaque (Figures 2A and 3). We found 
that there are equal amounts of macrophages in either half of the LSS lesion 
(27.4% ± 2.8% vs. 23.9% ± 2.2%), as indicated by the presence of CD68.  In 
the OSS segment the amount is significantly lower (8.7%), confirming previous 
findings in this model. 
As CD68 is a general macrophage marker, not reflecting the immunological 
activity of the cells, we measured the expression of MHC class II as a general 
indicator for macrophage activation(10) (Figures 2B and 3). Remarkably, despite 
the equal amounts of macrophages in the two LSS segments, we found MHC 
class II to be much higher expressed in the upstream half of the lesion (15.3% ± 
3.0% vs. 6.9% ± 1.9%, p<0.01). When evaluating the distribution of MHC class 
II cross-sectionally, we noticed that cells close to the luminal border of the lesion 
more often expressed this marker, suggesting that these were recent immigrants 
into the plaque (Figure 3).
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Figure 2. Characteristics associated with an unstable plaque phenotype are unequally distributed along 
the plaque length. A flow-altering device around the common carotid artery of ApoE-/- mice induced 
different shear stress profiles, resulting in unstable atherosclerotic lesions in the low shear stress (LSS)-
induced plaques, whereas the plaques induced by oscillatory shear stress (OSS) are stable. We divided 
the LSS plaque into an upstream and a downstream segment and compared vulnerability-determining 
factors with each other. We found differences in CD68 (A) and MHC class II (B) and matrix-degrading 
gelatinase activity (D) between the different segments. Also, we found a trend of collagen (C) in the 
upstream segment. We also tested for SMC α-actin (E) and HSP-47 (F), the latter tended was increased 
in upstream segments of the LSS plaque. These differences did not reach statistical significance, 
probably due to the limited number of samples available for analysis.
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Collagen tends to be lower in the upstream segment of low shear 
stress induced lesions
The most important matrix component determining the stability of a lesion is 
collagen. When comparing the amount of collagen between the two LSS segments, 
we found no statistically significant difference between the two LSS segments 
(Figures 2C and 3). Nevertheless, there is a clear trend showing a 23% lower 
collagen content in the upstream segment (8.7% ± 2.2 vs. 11.3% ± 1.6, p=0.17). 
We confirmed that the OSS segment contained a significantly higher amount of 
collagen (29.4%) compared to both LSS segments, as was found before(4). 
Figure 3. Histological representation of the longitudinal expression of markers associated with plaque 
instability. These images show representative histological sections taken along the length of a low 
shear stress plaque and the oscillatory shear stress plaque. Compare with Figure 1 for the approximate 
location in the lesion from which the sections originate. All photographs have been made with the 
same magnification (100x). A scale bar is provided in the lower right corner of the upper left figure and 
represents 100 μm. 
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Matrix-degrading gelatinase activity is most prominent in the 
downstream segment of the lesion and is partly dissociated from 
macrophage activation.
Since destabilization of atherosclerotic lesions is partly explained by matrix 
degradation mediated by macrophage-derived proteases, we performed in situ 
zymography to show gelatinase activity in the lesions. The highest gelatinase 
activity was observed in the downstream part (24.1% ± 2.5% vs. 12.7% ± 2.7%, 
p<0.01) (Figures 2D and 3), indicating that it is not fully related to macrophage 
activation as evidenced by MHC class II expression. Smooth muscle cells can 
also produce these matrix-degrading proteases, but the expression of SMC alpha-
actin was equally distributed (7,8% ± 2.3 vs. 7.9% ± 2.2%)(Figures 2E and 3). 
Collagen production tends to be higher in the upstream segment of 
the LSS plaque segment
The unexpected distribution of gelatinase activity, inspired us to investigate 
collagen production as well. Therefore, we measured the expression of the 
chaperone molecule Heat Shock Protein 47 (HSP-47), which presence closely 
reflects collagen production(11). We found that HSP-47 expression was almost 
threefold higher in the upstream segment compared to the downstream segment 
Figure 4. HSP-47 is inversely related to collagen expression. High expression of HSP-47, a chaperone 
protein indicative of collagen production, correlates with low presence of collagen in LSS-induced 
plaques. We histologically quantified the expression of HSP-47 and collagen in adjacent sections and 
used the Spearman non-parametric correlation test to test for correlation. We found that low collagen 
presence in plaque is associated with high expression of the collagen production marker HSP-47.
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Figure 5. Colocalization of HSP-47 with cellular components of a plaque. Expression of HSP-47, a 
collagen production-associated chaperone, only occasionally co-localizes with macrophages and SMC. 
Fluorescent double stainings were performed of HSP-47 with (A) macrophages (anti-CD68) and (B) 
SMC (anti-SMC α-actin) to find the cellular source of the production of collagen. Only occasionally we 
found single cells that expressed both markers (indicated by white arrows). White boxes in the overview 
pictures indicate the location of the enlargements. HSP-47 staining is displayed in red; CD68 and SMC 
α-actin are displayed in green (panel A and B, respectively). Nuclei are stained by DAPI and displayed 
in blue. 
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(14.5% ± 2.7% vs. 5.9 ± 1.3%)(Figures 2F and 3). However, these differences 
were borderline statistically significant (p=0.06), due to the limited amount of 
available samples (n=4). Despite the small sample size, this finding suggests that 
the presence of collagen fibers and the expression of HSP-47 are inversely related. 
This notion is indeed confirmed by correlation analysis (Spearman r = -0.54, 
p<0.001) (Figure 4). When assessing the distribution of HSP-47 on a cross-
sectional level, we noticed that HSP-47 expression was found throughout the 
entire lesion in the upstream part of the LSS segment, whereas in the downstream 
part most HSP-47 was found near the medial border of the plaque (Figure 3). 
To establish the source of the HSP-47, we also performed double staining with 
SMC α-actin and CD68 (Figure 5). We found that both α-actin-positive SMC 
and CD68-positive macrophages express HSP-47, but that the bulk of HSP-47 
did not match with either marker.
Discussion
The aim of this study was to characterize the various vulnerability-determining 
factors in LSS-induced atherosclerotic plaques in mice and relate these findings 
to their location in the plaque. To determine plaque vulnerability we assessed 
the following features: evidence of plaque disruption, the presence, production 
and degradation of collagen, the activation of macrophages, and the presence of 
SMC. We found frequent plaque disruptions only in the upstream part, which 
associated with macrophage activation. Collagen presence in this segment 
appeared to be slightly lower than in the downstream part, and, surprisingly, this 
was accompanied by an increased level of collagen synthesis and a lower level of 
degradation. Our main findings are summarized in Figure 6 and will be further 
discussed below.
We observed that disruptions of the unstable plaque, as indicated by intraplaque 
hemorrhages, occur predominantly in the upstream half of the lesion and never 
occur in the stable OSS-induced plaque. This reflects the localization of plaque 
ruptures in humans, which has been shown extensively to be more prominent 
in the proximal part of the lesion(8, 9, 12). Interestingly, disruptions in our 
model are exclusively located near the medial border of the lesions and appear 
as dissections of plaques from the elastic media or as canalization of basal plaque 
layers. In contrast to the situation in human, we have never observed rupture of 
the fibrous cap near the luminal side of the lesion, nor have we found evidence of 
previous ruptures by deposition of erythrocyte particles at this location. Notably, 
most plaque disruptions arise from the growing, proximal end of the plaque, but 
continue deep into the length of the plaque.
In order to study the role of activated macrophages in the process of destabilization 
in our model, we evaluated the distribution of the general macrophage activation 
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marker MHC-class II, which is known to be up-regulated by different activating 
stimuli, including pro-inflammatory cytokines and modified LDL that also induce 
gelatinase expression(10, 13). We found that expression of MHC class II was 
much higher in the upstream segment compared to the downstream LSS segment. 
Also, we noticed that most MHC class II-positive cells were found just below 
the endothelial cell layer, suggesting that these cells were recent immigrants into 
the plaque by transendothelial migration. The cellular morphology and location 
associated with MHC class II expression suggests that macrophages are the most 
likely candidates for MHC class II expression in our samples, especially since it 
is spatially related to CD68 expression, observed in adjacent sections. However, 
it must be noted that other plaque cell types, like endothelial cells, may express 
MHC class II as well(14). In contrast, near the sites of plaque disruption we found 
little or only very diffuse staining of MHC class II, implying remnant staining of 
deceased macrophages rather than viable activated cells, or the downregulation 
of MHC class II on plaque-resident cells. The latter is in accordance with the 
recently described finding that macrophages exposed to intraplaque hemorrhage 
adopt an atheroprotective phenotype, accompanied by a downregulation of MHC 
class II(15). 
We also studied the distribution of collagen and compared up and downstream 
segments of the unstable LSS-induced plaque. We found that there is no 
statistically significant difference in the distribution of collagen along the plaque, 
although there is a clear trend to less collagen in the upstream location. In general, 
our findings show that LSS-induced plaques, at 9 weeks after induction, have 
an unstable phenotype, while OSS-induced plaques may be considered stable, in 
accordance with results obtained previously in this model by Cheng et al1.
The accumulation of lesion-stabilizing collagen is the net result of the balance 
between (prior) collagen production and its degradation by proteolytic processes. 
Surprisingly, the expression of collagen synthesis-associated HSP-47 was highest 
in the collagen-low upstream segment. HSP-47 is known to reside selectively in 
the endoplasmic reticulum of collagen-producing cells(16, 17). Here it uniquely 
binds type 1 procollagen and functions as a molecular chaperone protein, crucial 
in the folding and secretion of type 1 collagen, the predominant type in human 
atherosclerotic lesions(2, 18). Accordingly, HSP-47 is being expressed in the 
fibrous regions of advanced plaques in mice(19), as well as in humans(20). 
We found that gelatinase activity was highest in the downstream segment of the 
LSS plaque, remarkably not matching the site with the disrupted lesions. Activated 
macrophages are regarded as culprits in destabilizing plaques, as they are a major 
source of matrix-degrading enzymes(21). Macrophages may express collagen-
degrading gelatinases (MMP2 and MMP9) upon activation by proinflammatory 
cytokines(22) or oxidized LDL(23). Both MMPs are expressed in mouse(24) and 
human lesions(25, 26) and are known for their potential to degrade the fibrous 
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cap(27). Macrophage activation as indicated by MHC class II expression and 
gelatinase activity were shown to be partly longitudinally dissociated, which leaves 
the question open what cell type is then primarily responsible for the enhanced 
production of gelatinases in the downstream LSS segment. It was shown 
before by us(28) and others(26) that α-actin-positive SMC may produce these 
enzymes as well. Co-localization of gelatinase activity and α-actin is present in 
our specimens, although most of it does not co-localize with either macrophage 
CD68 or α-actin. A possible explanation for these findings is that MMPs will 
be excreted into to extracellular matrix and therefore may dissociate from their 
producing cells. 
Together, our findings show a clear uneven distribution of plaque disruptions 
along the lesion in our model of low shear stress-induced atherosclerosis. The 
upstream location of disruptions is accompanied by macrophage activation as 
indicated by high expression of MHC class II and a trend towards decreased 
collagen presence. Unexpectedly, in segments with plaque disruption, collagen 
degradation seems to be lower and collagen production seems increased (Figure 
7). We believe that the plaque growth rate might be an important factor in the 
development of an unstable phenotype at the upstream segment of the LSS-
induced plaque. Due to rapid growth in the upstream direction there is little time 
to produce strong collagen-rich fibrous caps, resulting on proneness to disruption. 
The high expression of HSP-47 evidences the efforts to produce sufficient 
collagen. 
Figure 6. Summary of study results. 
This figure summarizes the results of the histological analysis. It depicts a plaque with an upstream (left) 
and downstream segment (right), with below the expression of the histological parameters. A bar with 
decreasing thickness represents a decrease in expression and vice versa.
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A remaining question is how well our model represents plaque vulnerability in 
humans. Clearly, significant similarities as well as differences were observed. 
The most obvious difference is the time needed to develop (unstable) disease, 
which is decades in humans vs. weeks in mice. Another major difference is the 
fact that this model does not display acute rupture of the fibrous cap. A detailed 
discussion about the possibility and significance of (signs of ) plaque rupture in 
mouse models in general can be found elsewhere (29, 30). However, despite these 
differences, the morphological similarities between the lesions induced in our 
model and unstable human lesions are plentiful and therefore support the model’s 
usefulness. The lesions show hallmark characteristics defined by the American 
Heart Association(1, 2) like: confluent cores of lipids, cores of necrotic cell debris, 
fibrous caps, as well as positive remodeling of the vessel wall. An additional 
significant advantage of this model is that it is based upon the concept of shear 
stress variations, which have shown to be important in humans as well(31-33). 
Furthermore, the model has been shown to be highly reproducible in the hands 
of multiple investigators, evidenced by the reproduction of previously found 
results(4, 7) in the current study. 
In summary, in this study we show that the vulnerability of atherosclerotic 
plaque induced by a low shear stress flow pattern is located predominantly in the 
upstream lesion segment. This is associated with activation of macrophages and a 
relatively low collagen content, but partly dissociated from gelatinase activity. This 
upstream vulnerability results frequently in disruption of the lesion, occurring 
primarily at the tunica media rather than at the collagenous cap. We believe that, 
when its limitations are respected, this model may be valuable for pathogenic and 
pre-clinical studies of unstable atherosclerosis.
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Abstract 
Background
We previously found that low shear stress induces atherosclerotic plaques 
with characteristics that include increased lipid and MMP content, and 
decreased vascular smooth muscle and collagen content. The mechanism 
is currently unknown. In the present study we evaluated the role of che-
mokines in this process. 
Methods and Results
Using an extra-vascular device, we induced regions of low, high, and low/
oscillatory shear stress (LSS, HSS, and OSS, respectively) in the carotid 
artery. Shear stress alterations induced expression of interferon γ indu-
cible protein-10 (IP10) in the LSS region, whereas monocyte chemoat-
tractant protein-1 (MCP1) and the mouse homologue of growth regu-
lated oncogene alpha (GRO-α) were equally upregulated in both LSS 
and OSS regions, one week after shear stress alterations. After 3 weeks, 
specific upregulation of GRO-α and IP10 was observed in LSS regions. 
After 9 weeks, lesions with thinner fibrous caps and larger necrotic cores 
were found in the LSS region compared to the OSS region. Equal levels 
of MCP1 expression were observed in both regions, while expression of 
fractalkine was found in the LSS region only. Results were confirmed 
on protein level by immunohistochemistry data. Blockage of fractalkine 
inhibited plaque growth, decreased lipid and CD68 accumulation, de-
creased the intimal necrotic core area, increased VSMCs and collagen 
content, and increased the fibrous cap thickness of atherosclerotic lesions 
in the LSS region.  
Conclusion
We conclude that LSS or OSS triggers expression of chemokines in-
volved in atherogenesis. Upregulation of fractalkine during LSS induced 
atherogenesis is critical in determining the phenotype of the atheroscle-
rotic lesion.
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Introduction
Shear stress, which is the drag force per unit area acting on the endothelium as 
a result of blood flow, plays a critical role in plaque location and progression (1, 
2). Both low shear stress and oscillatory shear stress have been implied as pro-
atherogenic in observational studies in humans and animals (1, 3, 4). Using a 
newly developed method to study cause-effect relationships of shear stress in vivo 
(5), we were able to demonstrate that low shear stress and oscillatory shear stress 
are both important stimuli for the induction of atherosclerosis (6). Remarkably, 
low shear stress induces the development of large-sized lesions with less lipids 
and MMP activity, and increased VSMCs and collagen content compared to the 
by oscillatory shear stress triggered lesions. 
Several studies indicated the role of inflammatory cells in the pathogenesis of 
plaques with a vulnerable phenotype (7-11). Furthermore, it has been postulated 
that rupture of vulnerable plaques is associated with activation of macrophages 
and of the adaptive immune system, leading to metalloproteinase activity and 
collagen breakdown (9, 12, 13). Accumulation of inflammatory cells occurs 
through a series of events consisting of rolling, arrest and migration (14, 15). 
Capture and initial rolling is induced by the interaction of several proteins, while 
arrest occurs predominantly by integrin-ligand interactions (16-18). The strength 
of the intergrin-ligand interaction is regulated through changes in avidity and 
affinity of the integrins (19). Shear stress plays an important role in this process 
as it counteracts the adhesion of the rolling cells (20, 21), and affects the density 
of adhesion factors (22, 23). Both in low shear and oscillatory shear stress fields, 
these two factors enhance the uptake of inflammatory cells. 
Recent studies indicate that avidity and affinity of integrins, are modulated by 
chemokines (17, 24). Chemokines are a family of small, secreted proteins consisting 
of C, C-C, C-X3-C and C-X-C subgroups based on the positioning of cysteine 
residues in their backbones (25). Data demonstrating a role for low or oscillatory 
shear stress in the regulation of chemokines come from a limited number of in 
vitro studies. These studies show a shear stress dependent expression of monocyte 
chemoattractant protein-1 (MCP-1/CCL2) (26, 27), and growth regulated 
oncogene alpha (GRO-α /CXCL8) (28). Chemokine specificity determines the 
type of inflammatory cells that migrate into the vessel wall. Hence, they might 
also modulate the phenotype of atherosclerotic lesion that develops in response 
to shear stress. The role of shear stress regulated chemokine expression during 
atherogenesis still needs to be investigated. Therefore, the aim of the study is 
to characterize the chemokine expression pattern in shear stress induced plaque 
formation. 
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Results
The effect of low shear stress and oscillatory shear stress on the development of 
atherosclerotic lesions 
Cast placement around the common carotid artery reduced shear stress upstream, 
and induced oscillatory shear stress downstream from the cast (5, 29). To study the 
effects of these shear stress fields on atherogenesis, a time series was performed 
(time points 1, 3, and 9 weeks, N = 5 mice per time point). No statistically significant 
differences in intimal/media ratio were observed between the different shear stress 
areas after 1 week of cast placement due to minimal atherogenesis (Figure 1A, B). At 
3 weeks, the intimal/media ratio in the low shear stress region was significantly larger 
than in the control region (Figure 1B), but the difference between oscillatory shear 
stress regions and control regions did not reach statistical significance. Evaluation of 
the intimal/media ratio at 9 weeks showed lesions in the low shear stress area that 
were larger in size compared to those in oscillatory shear stress (5 fold) and control 
(66 fold) regions. The intimal/media ratio in the oscillatory shear stress region was 
also larger (14 fold) than in the control region at this time point. Furthermore, 
lesions that developed under low shear stress conditions contained large necrotic 
cores underneath a thin fibrous cap, whereas the lesions in the oscillatory shear 
stress had a more “stable” morphology. These findings are in accordance with earlier 
obtained data (6).
Gene expression of specific chemokines characterizes low shear 
stress induced plaque development
To investigate the effect of low shear stress and oscillatory shear stress on chemokine 
expression under pro-atherogenic conditions, we screened the linearly amplified 
pools of antisense RNA from vessel segments exposed to the different shear stress 
conditions after 1, 3, and 9 weeks of cast placement in apoE-/- mice. Because no 
plaques were present in the low or oscillatory shear stress regions after 1 week of 
cast placement (Figure 1A, B), the results obtained from this time point show the 
effect of shear stress alteration on the vessel wall without an existing atherosclerotic 
lesion. In addition, the 3 weeks time point serves to study the effect of shear stress 
on the carotid artery with an early atherosclerotic lesion. Finally, at 9 weeks after 
cast placement, the specific chemokine expression of advanced lesions is analyzed. 
We compared the response of the chemokines MCP-1, GRO-α/KC, RANTES, 
eotaxin-1, ELC, SDF-1α, NAP-2, IP-10, fractalkine and CCL14 (all reported to 
be involved in atherosclerosis or to be regulated by shear stress (26, 28, 30)), on low 
and oscillatory shear stress stimuli at different time points. From the 10 chemokines 
investigated in this study, 4 (MCP-1, GRO-α/KC, IP-10, and fractalkine) were 
upregulated in response to alterations in shear stress at different time points. No 
shear stress responsive upregulation in the expression of the other chemokines 
(RANTES, eotaxin, ELC, NAP-2, SDF-1α and CCL14) was observed. After 1 
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Figure 1. Representative hematoxylin and eosin-stained cross-sections of murine carotid arteries at 
different time points after cast placement in mice on a Western diet. 
(A) Sections from the oscillatory shear stress region (OSS), low shear stress region (LSS) and undisturbed 
region (control) after one, three, and nine weeks of cast placement. The arrows in the pictures indicate 
accumulations of macrophages in fatty streaks (original magnification, 200X.). (B) Intima/media ratio in 
the control regions (hatched bars), the low shear stress regions (white bars), and the oscillatory shear 
stress regions (black bars) at the three different time points. *P<0.05 versus control. #P<0.05 versus low 
shear stress.  
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week, QPCR showed an increase in expression of the chemokines, MCP-1 and 
GRO-α/KC in the altered shear stress regions compared to control. In addition, 
IP-10 was more expressed in the low shear stress than in the oscillatory shear stress 
region. After 3 weeks of cast placement, the increased gene expression levels in 
MCP-1 were maintained in both low shear stress and oscillatory shear stress regions, 
while GRO-α/KC and IP-10 were only upregulated in the low shear stress region. 
After 9 weeks of cast placement the expression of MCP-1 and IP-10 returned to 
baseline levels. Of interest, fractalkine was only upregulated at this time point, and 
exclusively in the low shear stress regions.
Validation experiments
To verify the results obtained from the linearly amplified samples, we repeated 
the QPCR experiments with pooled samples of non-amplified RNA for those 
chemokines that were differentially upregulated. Essentially the same expression 
patterns were observed for MCP-1, GRO-α/KC, IP-10, and fractalkine (Figure 
2A, B, C, D) when we compared data from non-amplified RNA with data obtained 
with linearly amplified RNA. In particular the expression pattern of fractalkine were 
highly similar. 
In order to exclude possible non-shear stress related effects of the cast on chemokine 
expression, we performed control experiments with sham casts. These sham casts 
Figure 2:. Validation of the expression levels of the upregulated chemokines.  MCP-1 (Panel A), GRO-α/
KC (Panel B), IP-10 (panel C), and fractalkine (panel D) expression levels were measured by QPCR us-
ing pooled non-amplified cDNA samples (5 animals per pool, N=3) at different time points (1, 3, and 9 
weeks), and different locations (low, control and oscillatory shear stress regions). *P<0.05 versus control. 
#P<0.05 versus low shear stress. (E) Placement of a non-constrictive, control cast that does not alter the 
laminar shear stress, did not induce changes in gene expression.
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Figure 3. Confirmation of gene expression results of selected chemokines by immuno-histological 
analysis of the protein levels in carotid arteries at different time points after cast placement in mice on a 
Western diet. (A) Representative cross-sections of murine carotid arteries stained for fractalkine after 9 
weeks of cast placement, and MCP-1 and IP-10 after 1 week of cast placement, in the control, low and 
oscillatory shear stress regions (original magnification, 200X). Chemokine expression is represented by 
a red signal. Green auto-fluorescence is from the elastic laminae and demarcates the intimal and medial 
areas. (B) Immuno-histological quantification of the chemokine signals of the low shear stress (LSS), 
the oscillatory shear stress (OSS) regions and control regions are shown. N=5. *P<0.05 versus control. 
#P<0.05 versus low shear stress.
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Figure 4. Accumulation of CX3CR1+ cells in the different by shear stress induced mature athersclerotic 
lesions after 9 weeks of cast placement. 
(A) Representative cross-sections of murine carotid arteries stained for CX3CR1 (red signal) and nuclei 
(blue signal). Arrows indicate CX3CR1 positive cells. Asterisks indicate the position of the lumen, while 
the white dotted lines demarcate the boundaries between lumen and intima. (B) Immuno-histological 
quantification of the chemokine-receptor signal in the low (LSS) and the oscillatory shear stress (OSS) 
region. N=5. #P<0.05 versus low shear stress. 
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Figure 5. CX3CR1 expressing cells located in the advanced lesions are mainly monocytes and macro-
phages. Representative cross-sections of murine carotid arteries stained for CX3CR1 and CD11b (upper 
panels), CD68 (middle panels), and VSMC α-actin (lower panels), respectively. In the third panels, over-
lays show the co-localization signal in yellow. Asterisks indicate the position of the lumen, while the white 
dotted lines demarcate the boundaries between lumen and intima. Double staining for the identification 
of CX3CR1 expressing cell types has been repeated in 4 different experiments.
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were made of the same material as the real cast, but did not induce the alterations 
in shear stress due to a non-constrictive luminal geometry. Placement of the sham 
casts failed to cause lesion formation in both the upstream or downstream location 
from the device even after 9 weeks of instrumentation. Gene expression analysis 
on cDNA obtained from both locations did not reveal upregulation of MCP-1 or 
fractalkine (Figure 2E). 
Total cholesterol levels in plasma were increased in animals on the atherogenic 
Western type diet (1 week = 27.3± 2.0 mmol/l, 3 weeks = 22.4± 0.9 mmol/l, 9 
weeks = 24.3± 2.4   mmol/l) compared to animals on chow (10.9± 3.0 mmol/l). 
However, total cholesterol concentrations between animals treated with the cast or 
the non-constrictive sham cast were not different (9 weeks cast = 24.3± 2.4 mmol/l 
versus 9 weeks sham cast = 25.5± 3.0 mmol/l). Therefore, the observed variations 
in chemokine expression cannot be attributed to differences in plasma cholesterol 
levels.
Protein levels follow gene expression levels of selected chemokines
We evaluated the protein levels of a selected group of responsive chemokines. 
Fractalkine was studied, because it was the only chemokine with elevated 
expression in the atherosclerotic lesions induced by low shear stress that showed 
the interesting plaque composition. Indeed, a more intense fractalkine staining 
was found in the low shear stress region compared to the oscillatory shear stress 
and control regions (Figure 3A, B, upper panels) at 9 weeks, which is in accordance 
with the mRNA expression data. We also evaluated MCP-1, as the relevance 
of this chemokine for the pathology of atherosclerosis is well-known(25). 
Immunohistological analysis of vessel segments at 1 week, which is the time-point 
with the highest MCP-1 expression (see Figure 2), confirmed the upregulation 
of MCP-1 under both shear stress conditions (Figure 3A, B, middle panels). 
In addition, we selected one of the chemokines that were upregulated during 
early atherosclerosis development induced by low shear stress. The differences in 
protein level of IP-10 between the low shear stress and the oscillatory shear stress 
areas at 1 week of cast placement closely resemble the mRNA expression pattern. 
(Figure 3A, B, lower panels).  
Figure 6, right page: Fractalkine function was inhibited during cast-induced atherogenesis in 
ApoE-/- mice by administration of a neutralizing antibody from week 6 until week 9. Representative 
cross-sections are shown stained for: lesion morphology by hemotoxylin/eosin (A), macrophages (B), 
lipids (C), VSMCs (D), collagen (E), and fractalkine receptor (CX3CR1) (F). Asterisks indicate the position 
of the lumen, while the white dotted lines demarcate the boundaries between lumen and intima. Bar 
diagrams represent the lesion area and quantification of the (immuno-)histological analysis of the different 
plaque components. The percentages of positive area at time point 9 weeks in the intima in the low (LSS) 
and the oscillatory shear stress (OSS) region are indicated, comparing the control antibody group (-) with 
the α-fractalkine antibody group (+). N=8. *P<0.05 versus control antibody group.
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Fractalkine receptor expressing cells are present in the low shear 
stress-induced atherosclerotic plaques
 From the above findings, we concluded that fractalkine is an interesting chemokine 
for further studies. We therefore assessed the effect of low and oscillatory shear 
stress on the accumulation of CX3CR1 (i.e. the fractalkine receptor) positive cells in 
advanced lesions in order to determine its contribution to the pathology of the low 
shear stress lesions. CX3CR1 expressing cells were detected in the intimal area of 
lesions situated in the low shear stress region, while in the lesions in the oscillatory 
shear stress regions CX3CR1 expressing cells were hardly detected (Figure 4A, B). 
Further analysis of the atherosclerotic lesions located in the low shear stress area 
showed that many cells positive for CX3CR1 were also positive for the monocyte/
macrophage markers CD11b and CD68 in the lesions (Figure 5, upper and middle 
panels, respectively). Double staining for CX3CR1 and VSMC α-actin, did not 
show any obvious evidence for smooth muscle cells expressing the fraktalkine 
receptor (Figure 5, lower panels). Serial cross-sections show no general overlap 
of these CX3CR1+ cells with the fractalkine+ areas, indicating that most of these 
receptor positive cells do not produce the fractalkine ligand.
Inhibition of fractalkine function restrains growth and stabilizes 
atherosclerotic plaques induced by low shear stress
To evaluate the functional implications of above findings, we studied the possible 
effect of fractalkine inhibition on systemic effects, plaque composition and plaque 
vulnerability. Microscopic inspections of hematoxilin-eosin stained sections of 
liver, lung, spleen and draining lymph nodes of the carotid artery did not reveal 
any abnormalities in animals treated with the rabbit polyclonal IgG neutralizing 
antibody against fractalkine in the fractalkine group or the rabbit polyclonal IgG 
control antibody in the control group (data not shown). Furthermore, FACS analysis 
on spleen-derived and peripheral blood leukocytes showed no differences in the 
numbers of CD3+ cells or in the CD4+/CD8+ cell ratios between the two groups 
(data not shown). 
Animals in the fractalkine inhibition group showed a 50% reduction of plaque area 
in low shear stress regions only (Figure 6A), i.e. in the regions with a differential 
upregulation of fractalkine. In addition, fraktalkine inhibition changed plaque 
composition –with the exception of collagen– exclusively in the by low shear stress 
induced plaques: treatment with fractalkine-neutralizing antibodies approximately 
halved CD68 positive macrophage content and lipid accumulation in these type of 
atherosclerotic plaques compared with the control group and doubled the number 
of VSMCs (Figure 6A, B, C, and D). However, in the oscillatory shear stress regions, 
no differences between the fractalkine and the control group were observed in size 
and content of the plaques. In both the low shear stress regions and in the oscillatory 
shear stress regions, treatment with anti-fractalkine antibodies resulted in increased 
82
Chapter 4  |  Chemokines in Atherosclerosis
collagen content (Figure 6E). In both shear stress regions, no effect was found on 
the number of CX3CR1 positive cells in response to fractalkine antibody treatment 
(Figure 6F). 
Morphometric evaluation of the plaques in the low shear stress and the oscillatory 
shear stress region show that the relative cap area (cap/intima ratio) and the 
relative necrotic core size (core/intima ratio) were both ~2 fold smaller in the 
atherosclerotic lesions induced by low shear stress than by oscillatory shear stress 
(Figure 7). Treatment with anti-fractalkine antibodies resulted in an increase in 
cap thickness, and decreased the size of the necrotic core in the by low shear stress 
induced lesions (Figure 7).
Fractalkine might also affect the infiltration of other types of immune component 
cells involved in atherogenesis. Therefore, we analyzed the lesions induced by low or 
oscillatory shear stress from mice treated with the anti-fractalkine antibodies or with 
control antibodies for the accumulation of CD3+ (pan T cell marker) T cells, mast 
cells and NK cells. We found that fractalkine inhibition had no effect on CD3+ T 
cells accumulation (Figure 8A). However, inhibition of fractalkine function strongly 
reduced the numbers of mast cells in the adventitia of the plaques induced by low 
shear stress (Figure 8B). For the detection of NK cells, we used the anti-mouse 
Ly49G2 antibody, 4D11, which has no cross-reaction with macrophages and has 
been used previously for the detection of NK cells in murine plaque areas(31). In 
both the atherosclerotic lesions induced by low shear stress or oscillatory shear stress, 
NK cells were scarce, limited to one to two cells per lesion, and fractalkine inhibition 
did not show any effects. 
Figure 7. The effect of fractalkine inhibition on cap thickness and the size of the necrotic core in the low 
shear stress and oscillatory shear stress lesions. 
Quantification of cap thickness (left panel) and the necrotic core (right panel) relative to total intimal area 
of the low shear stress (LSS) and the oscillatory shear stress (OSS) regions, comparing the control anti-
body group (-) with the α-fractalkine antibody group (+).  N=8. *P<0.05 versus low shear stress without 
antibody treatment (-).
83
Figure 8. The effect of fractalkine inhibition on T cells (panel A) and mast cells infiltration (panel B, and 
Il-6 and CRP expression (panel C) in the low shear stress and oscillatory shear stress lesions. 
In the left panels, representative cross-sections taken from the low shear stress lesions (LSS) from ApoE-
/- mice after 9 weeks of cast placement with administration of rabbit IgG control antibodies (-) or with the 
neutralizing antibody against fractalkine (+) are shown. Cross-sections are stained for CD3+ T cells (A) 
and mast cells using toluidine blue (B) (original magnification, 200X). CD3+ T cells and mast cells are in-
dicated by arrows.  Asterisks indicate the intimal area. The number of positive cells counted in the intima 
(CD3+ T cells) and adventitia (mast cells) in the low shear stress (LSS) and oscillatory shear stress (OSS) 
lesions, with administration of rabbit IgG control antibodies (-) or with the neutralizing antibody against 
fractalkine (+). N=6. *P<0.05 versus control antibody group. (C) Expression levels of CRP and IL-6 in 
carotid arteries at 9 weeks after cast placement in mice on a Western diet in response to fractalkine inhi-
bition. Expression profiles were measured by QPCR using amplified RNA samples (10 animals per pool, 
N=3). In the control group (-), Il-6 and CRP levels in the low shear stress region are significantly upregu-
lated versus control and oscillatory shear stress region. *P<0.05 versus α-fractalkine antibody group (+). 
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Gene expression analysis of the different vessel segments at the 9 weeks time 
point revealed increased expression of the pro-inflammatory mediators CRP 
and IL-6 in the low shear stress versus the oscillatory shear stress regions in the 
control group. Fractalkine inhibition reduced gene expression of CRP and IL-6 as 
expression of these genes in the low shear stress areas were significantly decreased 
in response to antibody treatment (Figure 8C).
Subsequently, we investigated whether the effect of fractalkine inhibition is 
restricted to the lesions induced by the cast model. Therefore, the composition of the 
atherosclerotic lesions in the brachiocephalic arteries (BCAs) was analyzed. We found 
indeed effects of fractalkine inhibition on BCA lesions. Treatment with neutralizing 
antibodies against fractalkine reduced lipid and macrophage accumulation in the 
intimal area. It also increased the collagen content in these BCA lesions (Figure 9). 
No significant differences in the percentage of intimal VSMCs and lesion size were 
found, but a trend was observed towards a reduction in intimal area in response to 
the treatment (control group = 0.11 ± 0.01 mm2 versus fractalkine inhibition group 
0.08 ± 0.01 mm2). Discussion
The main findings of this study are: (i) the development of atherosclerotic plaques 
induced by low shear stress is characterized by a specific expression of GRO-α/
KC, IP-10, and fractalkine. (ii) Fractalkine determines the growth and the 
composition of this type of atherosclerotic lesion. 
The high mortality accompanying atherosclerosis can be ascribed to a large 
extent to rupture of vulnerable plaques (32, 33). The morphology of vulnerable 
plaques consists of a characteristic triad: a large lipid core, a thin fibrous cap and 
an accumulation of inflammatory leukocytes. This inflammatory component is 
prominent in plaques with a vulnerable phenotype, and it has been postulated that 
activation of the immune system is an important condition for the development 
of vulnerable plaques (7-11). Accumulation of inflammatory cells into plaques 
has been examined extensively and a cascade model has emerged from these 
studies. This model describes rolling, arrest and migration as a sequential process 
(9). Arrest of inflammatory cells on the endothelial layer in an arterial flow 
field, as occurs in our experiments, is due to an increased clustering on the cell 
surface (avidity) and increased affinity of integrins for their ligands (20, 21). Both 
processes are strongly modulated by chemokines (17, 24). However, the role of 
shear stress in the expression of chemokines largely unknown. 
We studied the effect of shear stress on chemokine expression, and thus potential 
leukocyte recruitment during plaque formation, performing a screening of 10 
chemokines that are known to be involved in the pathology of atherosclerosis 
or are known to be responsive to shear stress. Interestingly, 4 of the selected 
genes, MCP-1, GRO-α/KC, IP-10 and fractalkine, were upregulated. These were 
studied in more detail.  
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MCP-1 accumulation has been demonstrated in human atherosclerotic lesions 
and in plaques induced in animal models (34, 35). It is involved in monocyte/
macrophage recruitment and knock out studies indicate an important role in 
atherogenesis (25). In the present study, MCP-1 expression levels did not differ 
between low and oscillatory shear stress stimuli. These findings are in accordance 
with in vitro studies showing a role for both low and oscillatory shear stress in 
MCP-1 production by endothelial cells (26, 27). This lack in differential expression 
and the decline in MCP-1 expression after the first week of shear stress stimulation 
may imply that the MCP-1/CCR2 (MCP-1 receptor) interaction is important 
Figure 9: Fractalkine function was inhibited during atherosclerosis development in the BCAs in 
ApoE-/- mice on Western diet by administration of a neutralizing antibody from week 6 until week 9. 
Representative cross-sections are shown stained for: collagen (upper panels), lipids (middle panels), 
and macrophages (lower panels). Asterisks indicate the position of the atherosclerotic lesions. Bar 
diagrams represent quantification of the (immuno-)histological analysis of the different plaque compo-
nents. The percentages of positive area at time point 9 weeks in the intima in the BCAs are indicated, 
comparing the control antibody group (-) with the fractalkine antibody group (+). N=6. *P<0.05 versus 
control antibody group.
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predominantly during early atherogenesis, and may not play an important role in 
determining the phenotype of the advanced atherosclerotic lesion.  Recent studies 
with CCR2 deficient mice indicate that early reconstitution of CCR2 positive 
cells prevent the effects of CCR2 deficiency, while this effect is absent during later 
phases(36), similar to the present findings. 
Two other genes (IP-10 and GRO-α/KC) were upregulated in the early phase 
of low shear stress induced plaque formation. IP-10 is a chemoattractant for 
monocytes (37) and T-lymphocytes (38) and is induced by production of 
interferon-g (IFN-γ) (39). Only a small number of studies have identified 
this chemokine in relation with vascular disease. However, as IFN-g has been 
associated with vulnerable plaque formation (40), this chemokine may be of 
importance. Indeed, increased serum levels of IP-10 have been associated with 
coronary artery disease in patients (41). 
GRO-α/KC and its receptor CXCR-2 are involved in the accumulation of 
macrophages during atherogenesis, and high level expression of CXCR-2 by 
macrophages is detected in advanced lesions of patients and LDL receptor 
deficient mice (42). Surprisingly, increased GRO-α/KC expression was only 
detected at earlier time points (1 and 3 weeks). This implies that GRO-α/KC/
CXCR2 interaction is mainly involved during the early events of low shear stress 
induced plaque formation. 
From the upregulated chemokines, fractalkine is the only one that is exclusively 
expressed in the low shear stress-induced atherosclerotic plaque. Fractalkine is a 
unique chemokine that not only acts as a chemoattractant, but also as an adhesion 
molecule expressed on endothelial cells upon stimulation (43). The fractalkine 
receptor CX3CR1 is expressed on monocytes, macrophages, lymphocytes, 
VSMCs (44) and ECs, where its expression is regulated by IFN-γ (45, 46). 
Functional studies in mice indicate that CX3CR1 or fractalkine deficiency results 
in smaller atherosclerotic lesions, associated with a reduction in the number of 
macrophages and foam cells (47-49). In the present study, we observed more 
CX3CR1 positive cells in the plaques with the distinct composition located in 
the low shear stress region as compared to the plaques found in the oscillatory 
shear stress regions, suggesting that there is an effect of fractalkine expression 
on cell recruitment. Subsequent qualitative analysis of CX3CR1 positive cells 
identified predominantly monocytes and macrophages, and few VSMCs co-
localizing with the fractalkine receptor. It is postulated that monocytes may 
enter the atherosclerotic lesion from the adventitial side. However, in the lesions 
induced by low shear stress, cells positive for CD11b, which is a cell surface 
marker for monocytes that is downregulated during their differentiation into 
macrophages (50), were mainly detected just underneath the endothelium (Figure 
5). Additional studies in which we stained the lesions for the myeloid-committed 
progenitor cell marker er-mp53(51), showed er-mp53+ cells mainly located in 
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close proximity of the lumen (data not shown). We conclude from these data that 
plaque macrophages enter the lesions that are induced by low shear stress via the 
luminal side. 
Inhibition of fractalkine/CX3CR1 interaction decreased plaque growth, and altered 
the composition of the atherosclerotic plaques within the low shear stress regions. The 
exact mechanism is presently unknown, but might include a reduced accumulation of 
macrophages and foam cells, derived from CX3CR1high monocytes. In addition, the 
lesions contained increased amounts of extracellular matrix (collagen) and VSMCs, 
thereby increasing collagen synthesis, when compared with the lesions of the control 
group. Importantly, inhibition of fractalkine/CX3CR1 interaction had only minor 
effects on the lesions induced by oscillatory shear stress. This might indicate a role 
for low shear stress in the fractalkine-mediated effects. However, as fractalkine 
upregulation was only observed in the low shear stress plaques after 9 weeks of 
cast placement, other factors may be involved. For instance, extreme narrowing of 
the luminal area during later phases of plaque growth might have increased shear 
stress locally, and this increase in shear stress might have provided the trigger for 
fractalkine expression. In addition inflammatory mediators (e.g. IFN-γ) released 
from within the vessel wall during atherogenesis induced by low shear stress might 
also be responsible for the upregulation of fractalkine. Nevertheless, expression 
of fractalkine remains a distinct (indirect) effect of low shear stress-induction of 
atherosclerosis, and the results of the functional experiments presented in this study 
are important, as they clearly show the critical role of fractalkine in determining the 
composition of advanced atherosclerotic lesions. 
Recent in vitro findings obtained from flow chamber assays indicate that fractakine 
contributes to platelet activation and adhesion, and could therefore play an 
important role in increasing thrombogenesis in atherosclerosis(52). We studied 
platelet aggregation in the different shear stress lesions in response to fractalkine 
inhibition by immunohistochemistry, staining for P-selectin. Platelet aggregations 
were detected in both the low shear stress and oscillatory shear stress induced lesions. 
However, these vascular pathologies were also observed in fractalkine antibody treated 
animals. The platelets were activated, as platelet-leukocyte conjugates were formed 
lining the endothelium. Occasionally, large platelet-rich thrombi were detected in 
the lumen. As activated endothelial cells also produce P-selectin, we double-stained 
with antibodies directed against von Willebrand factor (green signal). The results 
show that these defined histological structures positive for P-selectin were indeed 
platelet aggregations lying on top of von Willebrand factor positive endothelial 
cells. These data indicate that fractalkine might not play a significant role in (micro)
thrombogenesis in vivo in the context of atheroschlerosis. It also seems not to be a 
prominent mechanism to explain the fractalkine effects.
The finding that fractalkine inhibition results in a decreased accumulation of mast 
cells in the adventitia of the by low shear stress induced lesions, is interesting as it 
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has been shown by Virmani and co-workers that mast cells infiltrate the adventitia 
of atherosclerotic vessel segments during plaque development in humans(53). 
Accumulation of mast cells in the adventitia is also increased in the coronary arteries 
of patients who died of acute myocardial infarction(54). It was speculated that 
the release of histamine and leukotrienes by activated mast cells in the adventitia 
could cause constriction of the atherosclerotic vessels, leading to acute coronary 
syndrome(55). Fractalkine has been shown to be involved in the recruitment of mast 
cells in skin tissue(56) and in the airway of patients with asthma(57). Our study 
now shows that chemotaxis of mast cells into the adventitia of atherosclerotic vessel 
segments is (partly) regulated by fractalkine. The inhibition of fractalkine function 
could therefore potentially provide an additional therapeutical advantage.   
In the studies conducted on the atherosclerotic lesions of the BCA, we show 
that the effect of fractalkine blockage is not restricted to lesions induced by the 
cast and that this chemokine is also involved in the progression of the disease 
at natural occurring predilection sites. The effects of fractalkine are mostly on 
atherosclerotic plaques with a distinct composition supporting a less “stable” 
phenotype, as both the low shear stress induced lesions(6) and the BCA 
lesions(58) show the occurrence of spontaneous intra plaque hemorrhages which 
are rare at other atherosclerosis-prone locations of the arterial tree, whereas the 
effects of fractalkine inhibition on the lesions induced by oscillatory shear stress 
were limited.  
A limitation to the current study is that by using whole homogenates from vessel 
tissue, we cannot distinguish in the mRNA data between changes in activation/
expression level per individual cell and changes in the number of cells expressing 
the chemokine of interest. Although the clear relation and effect of these 
identified chemokines on plaque composition prevail, it would be interesting 
to assess whether increased chemokine expression is derived from an activated 
subpopulation of intimal cells. Currently, we are conducting a large study in 
which we isolate specific cell types and subpopulations in the low and oscillatory 
shear stress lesions to evaluate their state of activation. In this study, we used 
an in house developed model for shear stress alteration to induce two types of 
atherosclerotic lesions. Although the lesions triggered by low shear stress show 
a less “stable” phenotype than the lesions induced by oscillatory shear stress, 
no plaque rupture was detected. Until now, actual plaque rupture has not been 
demonstrated unambiguously in any animal model. We did observe however that 
the atherosclerotic lesions in the low shear stress area in our model are more or 
susceptible to intraplaque hemorrhages. In addition, morphometric analysis of the 
low shear stress and the oscillatory shear stress regions indicate that they differ 
in fibrous cap thickness and necrotic core size. Taken together with the distinct 
difference in plaque composition between the atherosclerotic lesions induced 
by the two types of shear stress, we conclude that the cast model is suitable to 
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investigate the role of chemokines in determining plaque phenotype. 
In conclusion, the present study indicates that different shear stress fields have 
yielded different plaque compositions associated with different responses in 
chemokine expression. Low shear stress induces the development of larger lesions 
which characteristics point towards a less “stable” phenotype. These lesions are 
characterized by increased expression of multiple chemokines (GRO-α/KC, 
fractalkine and IP-10) compared to the oscillatory shear stress induced lesions. 
Fractalkine appears to be crucial in development of the distinct plaque phenotype 
that is induced by low shear stress triggering. Therefore, stabilization of this type 
of atherosclerotic plaques in patients by inhibiting fractalkine-fractalkine receptor 
interaction might provide an effective therapy. 
Materials and Methods
Mice
Mice deficient in apolipopotein E (apoE-/-) in a C57BL/6J background were 
obtained from Jackson Laboratory. Animals 15-20 weeks of age were assigned 
randomly to one of the 3 time points (see below). During the experimental 
period, all animals were fed a Western type diet consisting of 15% (w/w) cacoa 
butter and 0.25% (w/w) cholesterol (diet W, Hope Farms). After a two weeks 
period of Western diet, shear stress in the right common carotid artery was 
altered by cast placement as previously described(5). In short, the animals were 
anesthetized with isoflurane and the anterior cervical triangles were accessed by 
a sagittal anterior neck incision. Both halves of the cast were placed around the 
right common carotid artery and fixed with a suture, wounds were closed and the 
animals were allowed to recover. Animals with cast implants were sacrificed at 1, 
3, and 9 weeks after surgery. 
To study the effects of fractalkine blockage on plaque development, apoE-
/- animals were injected three times a week in the tail artery with 25mg of 
neutralizing rabbit a-mouse fractalkine antibody (Ebioscience) or rabbit IgG 
isotype control antibody (Ebioscience). Mice received the injections after six 
weeks of cast placement up until the 9 weeks time point at which the animals 
were sacrificed. The Erasmus MC institutional review board approved all animal 
studies described in this manuscript.
Gene expression analysis
Freshly isolated vessel segments were each divided into three different regions 
(0.5 mm proximal from the cast, 1 mm in the cast, and 0.5 mm distal to the cast) 
and pooled per region (n=10). Total RNA from the samples was extracted using 
the RNeasy kit (Qiagen) and was linearly amplified following an Eberwine T7 
90
Chapter 4  |  Chemokines in Atherosclerosis
protocol(59) or directly reversed transcribed into cDNA as indicated. Quantitative 
real-time PCR (QPCR) reactions were performed using a real-time fluorescent 
determination in the iCycler iQ Detection System (Biorad). Primers were 
designed for MCP-1, GRO-α, regulated upon activation, normal T cell expressed 
and secreted (RANTES/CCL5), eotaxin-1/CCL11, EBI-1-ligand chemokine 
(ELC/CCL19), stromal cell-derived factor 1a (SDF-1α/CXCL12), neutrophil 
activating protein 2 (NAP-2/CXCL7), interferon inducible protein-10 (IP-
10/CXCL10), fraktalkine/CX3CL1, and CC chemokine ligand-14 (CCL14). 
Target gene mRNA levels were expressed relatively to the housekeeping gene 
hypoxanthine guanine phosphoribosyl transferase (HPRT) as an endogenous 
control.
Cholesterol analysis
Blood samples were taken under anaesthesia by orbital puncture at the time of 
sacrifice. Total plasma cholesterol concentrations were measured enzymatically 
using a commercially available kit (kit 236691, Boehringer Mannheim GmbH). 
Histology
6 µm cryosections of the right and the left common carotid arteries or brachiocephalic 
arteries were obtained as described before(6). Sections equally spaced throughout 
the arteries at 120 µm intervals were used for analyses. Macrophages were 
detected using anti CD68 antibodies (Santa Cruz Biotechnology), and smooth 
muscle cells by antibodies against VSMC α-actin (Sigma, Chemical Co.,). Lipid 
deposition was analyzed with Oil red O staining and collagen with picrosirius 
red. Fraktalkine, MCP-1, IP-10 (Sigma Chemical Co.), and CX3CR1 polyclonal 
antibodies (Santa Cruz Biotechnology) and R594 or FITC labeled secondary 
antibodies (Molecular Probes) were used for analysis with a Zeiss LSM510LNO 
inverted laser scanning confocal microscope (Carl Zeiss). 
Quantification and statistics
Data analysis was performed using a microscopy image analysis system (Impak 
C, Clemex Vision Image Analysis System; Clemex Technologies). Intimal/media 
ratio was analyzed on haematoxylin/eosin stained sections. In order to quantify 
the expression of different chemokines in the vessel, the area positive for the 
specific staining was expressed as a percentage of the total area enclosed by the 
external elastic lamina and the lumen. To assess the percentage of the different 
plaque components, the area within the intimal positive for each staining was 
expressed as a percentage of the total intimal area. All cross sections stained were 
averaged per region of shear stress, i.e. low, oscillatory and high shear stress. For 
the morphometric analysis, the fibrocellular cap region was determined from 
collagen staining by picrosirius red and was expressed as a percentage of the total 
intimal area (cap/intima ratio)(60). The necrotic core region was determined 
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as an acellular area of the lesion (core/intima ratio)(60). Area was determined 
as acellular, lacking in nuclei and cytoplasm, from H&E stained sections. The 
necrotic core area was differentiated from regions of dense fibrous scars by the 
presence of macrophage debris. Statistical analysis was performed using one 
ANOVA analysis of variance followed by the Tukey test. Data are presented as 
mean ± SEM. P values <0.05 were considered significant.
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Abstract
Background
We previously found the chemokine CXCL10 gene to be specifically 
upregulated early during experimental development of plaque with an 
unstable phenotype. In this study we evaluated the functional consequen-
ces of these findings in mice and subsequently investigated whether these 
findings expressed importance for human vulnerable plaque development.
Methods and Results
In ApoE-/- mice, we induced unstable plaque with using a flow-altering 
device around the carotid artery. From week 1-4, mice were injected 
with a bioactivity-neutralizing CXCL10 antibody. After 9 weeks, lesion 
compositions of plaques were evaluated. CXCL10 inhibition resulted in 
a more stable plaque phenotype: collagen increased by 58% (p=0.002), 
smooth muscle cell content increased 2-fold (p=0.03), while macrophage 
activation as indicated by MHC class II expression decreased by 50% 
(p=0.005). Also, the size of necrotic cores decreased by 41% (p=0.01). 
Next, in 106 human carotid endarterectomy specimens we measured 
concentrations of CXCL10 protein and tested for association with pla-
que morphology. We found that increasing concentrations of CXCL10 
strongly associate with an increase in atheromatous plaque phenotype 
(ANOVA, p=0.003), with high macrophage, low smooth muscle cell and 
low collagen content.
Conclusions
In the present study we show that a causal relationship exists between lo-
cal production of CXCL10 and development of vulnerable plaque. Inhi-
bition of CXCL10 in a mouse model showed its functional involvement, 
while human endarterectomy analysis indicated an association between 
lesion morphology and the concentration of CXCL10. We conclude that 
CXCL10 might provide a new lead towards plaque-stabilizing therapy.
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Introduction
Atherosclerosis is a progressive inflammatory disease of the arterial vasculature 
with lesions that may turn unstable, which may lead to lesion rupture. The high 
mortality of these ruptures has been associated with atherosclerotic plaques that 
display a specific histological phenotype, characterized by a large pool of lipids and 
necrotic cell debris covered by a thin fibrous cap and the presence of inflammatory 
cells in the plaque shoulders1. 
Previously, we developed an experimental animal model in which plaques with 
stable and unstable characteristics are simultaneously induced in a single straight 
arterial segment2. We subsequently identified specific expression profiles of various 
chemokine genes in vulnerable plaque developement3. In these, the chemokine 
CXCL10 was specifically upregulated during the early phase in the development 
of the vulnerable plaque segment.
CXCL10 is a member of the CXC-family of chemokines. Upon stimulation with 
interferon-gamma (IFN-γ) it is expressed by many cell types, e.g. monocytes/
macrophages, endothelial cells, fibroblasts and natural killer-cells4, 5. Effects of 
CXCL10 are mediated by the G-protein coupled receptor CXCR3, which is 
known to be expressed by resting and activated T-cells, NK-cells as well as a 
subset of peripheral blood monocytes5-7. Furthermore, CXCL10 plays a variety of 
roles in inflammatory disease, like in the initiation and maintenance of T-helper-1 
(Th1)-polarized immune responses8, 9, migration of activated T-cells10, but also of 
natural killer cells11, of monocytes12, 13 and of smooth muscle cells (SMC)14.
Despite these compelling findings described in literature, in atherosclerosis 
CXCL10 has been less completely characterized. In human atherosclerosis, but 
not in healthy arteries, endothelial cells, smooth muscle cells and macrophages 
express CXCL1015. Functional observations in CXCL10 gene knockout mice 
indicated that CXCL10 exerts pro-atherogenic effects, probably related to the 
specific recruitment and retention of activated Th1 cells and downregulation of 
a regulatory T cell response16. While these findings indicate that CXCL10 plays 
a role in atherogenesis, its effect on plaque composition is unclear. Based on our 
previous observations on gene expression in the mouse model, we hypothesized 
that CXCL10 mediates development of vulnerable atherosclerotic plaque. Hence, 
we assessed whether CXCL10 plays a critical role in unstable plaque development 
by evaluating the effect of antibody-mediated functional inhibition of CXCL10 
on lesion phenotype in our vulnerable plaque mouse model. To provide evidence 
that the findings in the mouse bear relevance for human atherosclerosis, we 
also investigated the association between CXCL10 concentrations and plaque 
composition in human carotid endarterectomy lesions.
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Materials & Methods
Animals and surgical procedures
Apolipoprotein-E deficient mice, 15-20 weeks of age, were obtained from the 
Jackson Laboratories (Bar Harbor, ME, USA). They were fed a high fat, high 
cholesterol diet consisting of 15% (wt/wt) cocoa butter and 0.25% cholesterol 
(wt/wt) (Diet W, Hope Farms, Woerden, The Netherlands). Two weeks after 
this diet was initiated, the mice were instrumented with a shear stress-altering 
device around the right common carotid artery under 2% isoflurane anesthesia, 
as described previously2. Briefly, this device gradually narrows the vessel lumen to 
~70% of its original diameter. As a consequence, shear stress is lowered upstream of 
the device, gradually increases inside the device and is oscillating just downstream 
of the device17. After surgery, the mice were kept on the high fat, high cholesterol 
diet for the remainder of the experiment. The device remained in situ for 9 weeks. 
Intervention and control groups consisted of at least 10 animals per group. All 
animal experiments were approved by the institutional animal ethical committee 
and performed in compliance with institutional and national guidelines.
CXCL10 inhibition
Mice were intravenously injected three times a week in week 2-4 post-surgery 
with an anti-mouse bioactivity-neutralizing monoclonal CXCL10 antibody 
(MAB466, R&D Systems, Abingdon, United Kingdom) in a dose of 25 µg in 0.2 
ml sterile PBS. Untreated cast-instrumented mice served as control. 
Isolation and analysis of murine tissues
Following sacrifice, blood was collected and mice were flushed systemically with 
PBS. Next, the common carotid artery was isolated, embedded in OCT compound 
(Tissue-Tek, Sakura, Japan), and snap-frozen in liquid nitrogen. For histology, 8 µm 
cryosections were cut and stained for routine histology (Hematoxilin-Eosin, HE), 
lipids (Oil Red O), collagen (Picrosirius Red), macrophages (anti-CD68, AbD-
Serotec, Oxford, UK), macrophage activation (anti-Major Histocompatibility 
Complex (MHC) class II, clone M5/114, ATCC TIB-120) and smooth muscle 
cells (anti-SMC α-actin, Sigma-Aldrich, The Netherlands).  Subsequently, high-
resolution images ware taken using an Olympus BX-40 microscope or a Zeiss 
LSM5 Meta confocal microscope (Zeiss Jena, Germany). Collagen stainings 
were assessed using crossed circular polarization filters. To calculate lesion size 
and cellular content relative to the plaque area, all images were analyzed after 
digitalization by automated image analysis software (Clemex Technologies Inc, 
Canada) applying thresholding of the stained areas. Necrotic cores (defined as 
hypocellular plaque cavities devoid of collagen, containing cholesterol clefts) were 
assessed based on HE and Picrosirius Red stained sections and measured relative 
to the lesion area. Total cholesterol levels were measured in serum samples by an 
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enzymatic colorimetric method (Cholesterol E, Wako Diagnostics, USA).
Endarterectomy procedures
All patients in this study were participants of a prospective study aimed at 
investigating the predictive value of plaque characteristics for long-term outcome 
(AtheroExpress), of which the study methods have been described extensively 
before18. In short, all patients underwent carotid endarterectomy, during which 
arterial wall tissue was obtained. Next, the culprit lesion, defined as the segment 
with the largest plaque burden, was processed for histological examination. In 
addition to HE staining, sections were stained for collagen (Picrosirius Red), 
SMC (α-actin), and macrophage (CD68) content. Histological assessment was 
performed in a semi-quantitative fashion (none; minor; moderate; heavy), on basis 
of two independent observers. When results contradicted, a third independent 
observer was consulted. Subsequently, plaques were designated as fibrous (lipids 
constitute <10% of lesion surface area), fibro-atheromatous (10-40% lipids) or 
atheromatous (>40% lipids) based on collagen and HE stainings. Besides, plaques 
were also designated as SMC-dominant or macrophage-dominant based on the 
prevailing cell type obtained from the specific stainings. 
A 5 mm segment directly adjacent to the culprit lesion was crushed in liquid 
nitrogen, and subsequently total protein was extracted using 1 mL of Tripure 
Isolation Reagent (Boehringer Mannheim, Germany), according to the 
manufacturer’s protocol. Then, CXCL10 concentration was measured by Enzyme-
Linked Immuno Sorbent Assay (ELISA) according to manufacturers instructions 
(Quantikine human CXCL10 immunoassay, R&D Systems, Abingdon, United 
Kingdom), and blinded from histological and clinical data.
Statistical analysis
SPSS (version 15.0, SPSS Inc., USA) was used for all analyses. To test the 
differences between the treated and the control mice at 9 weeks of cast placement, 
a student’s T test was used. When these data had a non-Gaussian distribution, 
a non-parametric T-test was used. For the endarterectomy samples, to compare 
CXCL10 levels between categorical baseline and plaque morphology variables, 
Kruskal-Wallis and Mann-Whitney tests for non-Gaussian distributed data were 
used. To investigate the differences between continuous baseline variables and 
CXCL10, patients were categorized into quartiles, named 1 through 4 based 
on increasing CXCL10 concentration. Subsequently, these quartiles were used 
to sort all other variables. One-way ANOVA was used to compare continuous 
variables. The quartiles were also used to visualize the relationship between 
CXCL10 concentration and plaque morphology. Data are described as mean ± 
SD or median (Inter Quartile Range) as appropriate. A p-value of <0.05 was 
considered statistically significant.
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Results
Suppression of CXCL10 bioactivity inhibits experimental vulnerable 
plaque formation
As we previously found that CXCL10 is expressed specifically in developing 
unstable lesions3, we investigated if CXCL10 is also functionally involved in the 
development of plaque vulnerability using a mouse model that we developed 
before2. ApoE-deficient mice, in which a shear stress-altering device was applied, 
were injected with a bioactivity-neutralizing antibody during the onset of plaque 
formation. As expected, serum total cholesterol levels did not differ between 
treated and control mice (30.13 ± 4.6 vs. 29.92 ± 6.7 mmol/L, p=0.92). Short-
term inhibition of CXCL10 did not influence the extent of plaque development, 
since we found no difference in lesion size between the treated and the control 
mice after 9 weeks of shear stress alteration. Because macrophage foam cells are 
characteristic of atherosclerosis, we measured both plaque lipid (31.3 ± 8.0% 
treated vs. 29.5 ± 7.0% control) and macrophage content (31.7 ± 7.6% treated vs. 
27.8 ± 7.0 control; Figure 1A), where both remained unchanged upon CXCL10 
inhibition.
To assess plaque vulnerability, we determined the amount of collagen in the 
lesions, which is the main stabilizing component of the plaque. Interestingly, we 
found a 57% increase in the relative amount of collagen in the plaques following 
CXCL10 suppression (17.8 ± 6.5% vs. 11.3 ± 5.5%, p=0.002; Figure 1B). The 
amount of plaque collagen is essentially the result of a balance between collagen 
deposition and breakdown. Therefore, the increase in collagen may be the result 
of decreased breakdown predominantly by proteinases secreted by activated 
macrophages. To determine the extent of immune activation, we measured 
MHC class II by immunohistochemistry. The cellular morphology, location in 
the plaque and spatial association of MHC class II staining with macrophage 
staining by CD68 antibodies in adjacent sections (Fig.1A, C) strongly suggests 
Figure 1, right page: Anti-CXCL10 treatment in atherosclerosis susceptible mice results in a change 
into a more stable lesion phenotype. 
A flow-altering device around the common carotid artery induced atherosclerosis in ApoE-/- mice. From 
week 1-4 of lesion development, a bioactivity-neutralizing anti-CXCL10 antibody was injected. After 9 
weeks, lesions were compared to untreated controls by histology. The pictures show representative 
histological sections of treated and control mice. All photographs have been made with the same mag-
nification (100x). Scale bars are provided in E and represent 100 μm. Data in bar diagrams are the mean 
values ± SD of at least 8 sections from at least 10 different animals per group. CXCL10 inhibition resulted 
in a more stable morphology evidenced by: unchanged amounts of lesion macrophages (A), increased 
amounts of collagen (B), decreased macrophage activation (C), increased numbers of SMC (D) and 
reduced necrotic core size (E).  *p<0.05, **p<0.01.
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that MHCII-positive cells are the prime cells expressing this activation marker. 
We found a 50% reduction in the plaque MHC class II levels following CXCL10 
inhibition (6.3 ± 3.3% vs. 12.6 ± 7.4%, p=0.005; Figure 1C).  In addition, the 
amount of SMC, which are known to produce collagen, nearly doubled in the 
CXCL10-suppressed group (13.5 ± 8.4% vs. 6.3 ± 7.0%, p=0.03; Figure 1D), 
suggesting that the differences in collagen content may be explained by several 
factors.
The necrotic core is a hallmark component of the vulnerable plaque. To test 
whether CXCL10 inhibition reduces necrotic core formation, we analyzed both 
the number of necrotic cores in the lesions as well their relative size. We found 
that CXCL10 inhibition resulted in fewer necrotic cores: 38.9 ± 22.1% vs. 57.7 ± 
20% of the sections covering the entire lesion contained a necrotic core (p=0.02). 
Moreover, also the relative size of the necrotic cores decreased following antibody 
treatment from 26.4 ± 11.4% to 15.6 ± 6.1% of the plaque surface area (p=0.01; 
Figure 1E).
Figure 2. Distribution of CXCL10 measurements from each patient across quartiles. Atherosclerotic 
plaques were obtained from 106 patients during carotid endarterectomy. In the plaque segment directly 
adjacent to the culprit lesion, the content of the chemokine CXCL10 was measured by ELISA. Based on 
these measurements, patients were divided into one of four quartiles according to the CXCL10 concen-
tration. Quartile 1 represents the lesions with the lowest CXCL10 values, whereas quartile 4 contains the 
highest. This figure shows the individual measurements for all patients and the distribution across each 
quartile of plaque CXCL10. Horizontal bars represent the median concentration of each quartile.
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Patient characteristics
For this study endarterectomy specimens of 106 patients were analyzed. An 
overview of the patient characteristics is provided in Table 1. Histological 
examples of the lesions are shown in a previous publication by Verhoeven et 
al18. The CXCL10 concentration in the specimens ranged from undetectable to 
384.8 pg/mL, with a median (interquartile range) of 38.34 pg/mL (14-39 pg/
mL). To compare continuous CXCL10 levels to the categorical variables, patients 
were categorized into quartiles (Figure 2). The variables were then tested for 
changes across the quartiles. No differences were found comparing risk factors for 
atherosclerotic disease. The use of medication did not differ significantly between 
the quartiles. 
Clinical 
Characteristics
Total
Quartile of CXCL10 concentration
p-value*
1 2 3 4
CXCL10 pg/mL
38.3 
(14-40) †
0-11.3 11.8-18.4 19.3-37.2 37.6-382.6 0.000
Age (years)† 68.4 ± 8.9 66.0 ± 8.0 68.3 ± 10.2 67.7 ± 8.2 71.2 ± 8.5 0.157
Male (%) 73.6 73.1 70.4 66.7 84.6 0.316
Hypertension (%) 71.7 80.0 70.4 66.7 79.2 0.764
Smoker (%) 24.5 30.8 18.5 32.0 19.2 0.476
Symptomatic disease 
(%)
86.8 84.6 85.2 92.6 84.6 0.762
Statin (%) 56.6 66.7 55.6 55.6 56.0 0.530
β-blocker (%) 39.6 37.5 33.3 56.0 41.7 0.321
ACE-inhibitor (%) 39.6 42.3 33.3 40.7 42.3 0.881
Serum values†
Total cholesterol 
(mmol/L)
4.9 ± 1.3 4.8 ± 0.9 5.2 ± 1.3 4.8 ± 1.7 4.6 ± 1.2 0.564
HDL (mmol/L) 1.2 ± 0.4 1.2 ± 0.4 1.4 ± 0.3 1.1 ± 0.3 1.1 ± 0.4 0.156
LDL (mmol/L) 3.0 ± 1.1 2.7 ± 0.8 3.3 ± 1.0 3.2 ± 1.4 2.7 ± 1.0 0.392
Triglycerides (mmol/L) 1.9 ± 0.9 2.3 ± 1.0 1.8 ± 0.8 2.0 ± 1.1 1.7 ± 0.7 0.434
ApoB (mmol/L) 0.9 ± 0.2 0.9 ± 0.2 1.0 ± 0.2 1.0 ± 0.3 0.9 ± 0.3 0.787
Glucose (mmol/L) 6.6 ± 1.9 5.8 ± 0.7 7.0 ± 2.0 7.0 ± 2.3 6.4 ± 1.9 0.129
CRP (mg/mL)
3.40
(1.6-7.3)
3.13
(1.4-5.8)
2.96 
(1.8-5.8)
4.81 
(1.7-9.1)
4.52 
(1.6-7.3)
0.221
Table 1. Patient baseline measurements for carotid endarterectomy specimens. 
Baseline data of 106 patients were stratified into four quartiles according to plaque CXCL10 concentration. 
†Values are represented as mean ± SD or median (Inter Quartile Range) as appropriate. *p-values based 
on ANOVA test between CXCL10 quartiles for continuous variables, and non-parametric Mann-Whitney 
test for categorical variables.
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High CXCL10 concentrations identify patients with a more vulnerable 
plaque phenotype
Several significant associations were found between plaque composition and 
CXCL10 levels. Atheromatous lesions were more prominent at higher CXCL10 
concentrations than those classified as fibrous (Rank 53 vs. 45, p=0.003). Also, 
higher CXCL10 concentrations were associated with more macrophage-dominant 
plaques (Rank 56 vs. 41, p=0.009), and fewer smooth muscle cells (Rank 39 vs. 74, 
p=0.001) and less collagen (Rank 37 vs. 63, p=0.003). 
Subsequently, we analyzed the association between plaque composition and 
CXCL10 levels, by dividing patients into quartiles based upon CXCL10 
concentration. More atheromatous lesions were represented in the higher quartiles, 
while fibrous lesions were more frequently present in the lower quartiles (Figure 
3A). Macrophage-dominant lesions were mostly found in the top quartiles of 
CXCL10 content, while SMC-dominance associated with lower CXCL10 
concentrations (Figure 3B). However, no differences were seen in the macrophage 
staining between the quartiles (Figure 4A). This paradox was the result of an 
inverse relation between smooth muscle cell staining and increasing CXCL10 
concentrations (Figure 4B). Additionally, more collagen staining was seen in the 
plaques in the lower quartiles (Figure 4C).
Figure 3. Plaque concentrations of CXCL10 are associated with lesion morphology. 
Individual values were divided over quartiles (see Fig.1). By using ANOVA, we tested to see if plaque 
CXCL10 concentrations associated with lesion morphology. Increasing plaque concentrations of 
CXCL10 were indeed associated with an increase in atheromatous-type lesions (A) and a decrease of 
SMC dominant lesions and an increase of macrophage dominant lesions (B).
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Discussion
This study may be summarized by its two main findings. First, we showed a 
functional role of CXCL10 in vulnerable plaque formation in an experimental 
mouse model for unstable atherosclerotic disease. We observed that inhibiting 
CXCL10 with a bioactivity-neutralizing antibody resulted in plaques with less 
macrophage activation, with more SMC and a subsequent increase in collagen 
content compared to controls. A decreased number and size of necrotic cores 
in the lesions of the treated animals further substantiated these findings. This 
resulted in a lesion phenotype with increased intrinsic stability.
Second, we found that in human carotid plaques, CXCL10 levels are associated 
with lesion morphology. This is evidenced by an increased number of atheromatous 
plaques with increasing CXCL10 concentrations, and by the association with 
unstable plaque characteristics, such as macrophage dominance and reduced 
Figure 4. Increasing carotid plaque CXCL10 concentrations are associated with a less fibrous pheno-
type. 
Plaque concentrations of CXCL10 were associated with histological qualities of the lesion by ANOVA. 
Staining for macrophages, SMC or collagen was quantified as none, minor, moderate or high. Based on 
these qualifications a weighed value for average staining intensity was calculated (1, none; 2, minor; 3, 
moderate; 4, heavy staining). Macrophage staining was not associated with plaque CXCL10 (A), whereas 
high plaque concentrations of CXCL10 were associated with decreasing amounts of smooth muscle 
cells (SMC) (B) and decreasing collagen (C).
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presence of smooth muscle cells and collagen.
Previous studies have shown that inhibition of CXCL10 by antibodies in an 
intestinal inflammation animal model is an effective way to inhibit its function19, 
20. The findings in those studies have been ascribed to the reduced amount of 
Th1 cells that were recruited to the diseased sites and either reduced production 
of inflammatory cytokines19 or resulted in inflammatory disease exacerbation20, 
depending on the role of T-cells in the pathogenesis of the disease.
The lesion-stabilizing effect we observed by inhibiting CXCL10, might be 
explained by a similar mechanism as described above, as it has been shown before 
that inhibition of the CXCL10-CXCR3 pathway decreases the amount of lesional 
T-cells16, 21. Veillard et al reported that genetic deletion of CXCR3 in ApoE 
knockout mice reduced early lesion formation, which correlated with an increase 
in lesional FoxP3-positive regulatory T-cells 21. Recently, it has been reported 
that genetic deletion of CXCL10 in atherosclerosis-susceptible mice also resulted 
in smaller lesions, which contained fewer CD4+ T-cells16. Surprisingly however, 
despite the decrease in overall T-cell presence in the lesions, a higher expression 
of FoxP3 as well as of the anti-inflammatory cytokines IL-10 and TGF-β mRNA 
was found. This suggests a more prominent role for regulatory T-cells in this 
model. A similar increase in FoxP3 and TGF-β expression was found in a study 
using a peptide antagonizing CXCR3 in LDL receptor knockout mice, resulting 
in smaller lesions in the aortic root and the aorta22. 
A general limitation of our experimental mouse model is that there are few 
T-cells in the induced lesions after 9 weeks of cast placement, approximately 
2-4 per lesion cross section3. As a consequence, we have been unable to find a 
difference in T-cell numbers following CXCL10 inhibition (data not shown). 
Nevertheless, the reduction in T-cells might have taken place during the early 
phase of actual inhibition. We performed measurements at only one time point, 
while the presence of T-cells in a lesion changes over time23. Also, the effect of 
small numbers of T-cells might prove to be very strong24. 
The small numbers of T-cells do not allow to produce sufficiently reliable data 
to enable making a comparison with the situation in mice that are deficient in 
CXCL 10 by gene targeting. This cannot be solved by mRNA analyses, as there 
was no RNA available from the endarterectomy  samples that have been used. 
Besides facilitating recruitment of leukocytes, CXCL10 also induces and sustains 
a dominant Th1-type response by increasing the production of IFN-γ, providing 
a positive feedback loop25. Neutralization of CXCL10 might therefore result 
in a decreased concentration of IFN-γ in the lesions, which is considered a key 
cytokine in disease progression26 and macrophage activation27. This notion is in 
agreement with our findings regarding macrophage activation status as measured 
by MHC class II expression27, SMC presence27 and collagen accumulation28.  
An alternative or additional mechanism of plaque modification by CXCL10 
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inhibition might be operative as well. Not only Th1 and NK cells, as major IFN-g 
producers, are responsive to CXCL10, but also plasmacytoid dendritic cells (PDC) 
express CXCR3 and are recruited via this receptor29. The numbers of circulating 
PDC are reduced in human atherosclerosis, while immunohistochemical analysis 
has indicated that they are recruited to advanced plaques30,31. PDC are known to 
produce large quantities of IFN-a upon activation and this cytokine functions as 
an inflammatory amplifier in the atherosclerotic plaque32. Additionally, a minor 
subset of monocytes has been shown to be recruited via CXCR3 to inflammatory 
environments7 and might thus contribute to plaque instability as well.
Further research is needed to understand the mechanisms underlying the effects 
of CXCL10 inhibition. E.g., apoptosis could have an important role in the 
observed differences in plaque composition and size. It could be of interest to 
study the role of SMC in more detail by staining serial sections for proliferation 
and apoptosis on the one hand and alpha actin on the other hand. In addition, in 
situ zymography studies could be performed to get a clearer idea of the possible 
role of collagenolytic activity in the lesions. It would be very interesting to know 
more about the role of the pro-inflammatory cytokine microenvironment in the 
plaque in the experiments with CXCL 10 inhibition. From the present data, we 
cannot exclude that by inhibiting CXCL10 we just postponed the process of the 
lesion formation and maturation, rather than permanently altering it. For this 
argument and because of the ongoing discussion on the quality of animal models 
representing human disease states, we also performed a parallel study in humans.
Mach et al15 were the first to associate CXCL10 with human atherosclerosis, 
reporting that CXCL10 was expressed in several stages of the disease. CXCL10 
was shown to be present on the surface of endothelial cells, suggesting a role in 
the recruitment and adhesion of CXCR3-positive cells from the circulation. They 
also showed broad expression of CXCL10 by SMC and macrophages throughout 
the lesion. Little is known about the effects of CXCL10 on human atherosclerosis 
development and clinical outcome. Previous studies sought to correlate plasma 
CXCL10 levels with the occurrence of coronary heart disease (CHD). In a case-
control study it was found that CHD risk was associated with an increase in 
serum CXCL10.33 A later prospective study showed that indeed increased levels 
of CXCL10 exist prior to CHD, but was not considered an independent risk 
factor34. Our study is the first one to correlate lesional CXCL10 protein content 
with plaque morphology in humans and to be a possible predictor of plaque 
vulnerability. Obviously, this cannot be measured directly in living patients, so it 
would be of interest to know the correlation between lesional and systemic levels 
of CXCL10. There were no plasma samples available to measure the systemic 
CXCL 10 levels and correlate them to the lesional levels, so this has to await 
future work.
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In conclusion, we showed that the chemokine CXCL10 plays a functional role in 
the destabilization of atherosclerotic plaques in mice and is specifically upregulated 
in vulnerable plaques in humans. Since the experimental data were paralleled by 
similar findings in human unstable lesions, CXCL10 might be regarded as a new 
lead into understanding the process of plaque destabilization. 
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Abstract
Background
Underlying mechanisms of the differential development of atherosclero-
tic plaques into stable or unstable lesions are currently unclear.
Aim: To evaluate whole genome genetic expression profiles of stable 
and unstable plaques during their development in order to gain further 
insight into plaque growth in general, but also into the differentiation 
mechanisms of lesions.
Methods and Results
Using a flow altering device, both stable and unstable lesions were 
developed in atherosclerosis susceptible mice in oscillatory (OSS) and 
low shear stress (LSS) conditions respectively. After either 6 or 9 weeks, 
plaque tissue was harvested by laser microdissection and RNA was ex-
tracted, linearly amplified and analyzed by whole genome microarrays. 
Highly expressed genes were stained by immunohistological techniques.
Results: Differentially expressed genes were only found between LSS 
and OSS segments after 6 weeks of plaque development, most of them 
involved in neuronal pathways. Immunohistological staining was unable 
to confirm the genetic data.
Conclusion
These data should be considered inconclusive. Repeating experiments are 
necessary, combined with validation by qPCR.
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Introduction
Vulnerability of atherosclerotic lesions and the inherent risk of plaque rupture 
are a major clinical problem. An unstable lesion characteristically has a large lipid 
core and a thin overlying fibrous cap. Loss of fibrous cap material is mediated 
by breakdown of collagenous structures due to the proteolytic activity of matrix 
metalloproteinases (MMP). Vascular smooth muscle cells (SMC) play an essential 
role in the formation of the fibrous cap.  During lesion progression, contractile 
SMC migrate from the tunica media to the newly formed neointima. The SMC 
will dedifferentiate from their contractile phenotype into a synthetic phenotype, 
and start to produce extracellular matrix components like collagen. Thus, cap 
thickness results from the balance between collagen synthesis by the SMC and 
degradation by MMP.
Previously, we developed an experimental animal model in which both plaques 
with stable and unstable characteristics are simultaneously induced in a single 
straight arterial segment. This model is based on a device that alters the blood flow 
and therefore induces different shear stress patterns. Briefly, this device gradually 
narrows the vessel lumen to ~70% of its original diameter. As a consequence, 
shear stress is lowered upstream of the device (low shear stress; LSS), gradually 
increases inside the device (high shear stress; HSS) and is oscillating (oscillatory 
shear stress; OSS) just downstream of the device1. Nine weeks after placement of 
the device in atherosclerosis-susceptible mice, the lesions in the LSS segment had 
the characteristics of an unstable plaque with a necrotic core and thin fibrous cap, 
whereas the OSS segment displayed a stable phenotype with increased presence 
matrix-producing SMC and collagen and reduced gelatinolytic activity. The HSS 
segment remained free of atherosclerosis.
Since the underlying mechanisms resulting in these two distinct morphologies 
are unclear, we evaluated the genetic expression profiles of the lesions from LSS 
and the OSS segments during their development, by whole genome microarray 
analysis. Using this approach we aim to get further insight into plaque growth in 
general, but also what mechanisms may play a role in the differentiation of the 
two plaque phenotypes. The results could lead to new hypotheses with regard to 
atherosclerosis, which can be studied in the future. Hence, the aim of this study 
was not to explore the newly found mechanisms in depth.   
Materials and Methods
Animals and surgical procedures
Apolipoprotein-E deficient mice, 15-20 weeks of age, were obtained from the 
Jackson Laboratories (Bar Harbor, ME, USA), and fed a high fat, high cholesterol 
diet consisting of 15% (wt/wt) cocoa butter and 0.25% cholesterol (wt/wt) (Diet 
W, Hope Farms, The Netherlands). Two weeks after this diet was initiated, the 
119
mice were anesthetized with 2% isoflurane and instrumented with a shear stress-
altering device around the right common carotid artery, as described previously2. 
Mice were kept on the high fat, high cholesterol diet for the remainder of the 
experiment. The device remained in situ until sacrifice after 6 or 9 weeks. At 
each time point, six mice were used for genetic analysis and another three for 
histological validation of expression results.  
All animal experiments were approved by the institutional animal ethical committee 
and performed in compliance with institutional and national guidelines.
Tissue preparation
Following sacrifice, blood was collected and mice were flushed systemically 
with PBS treated with the RNase inhibitor diethylpyrocarbonate (DEPC). 
Subsequently, the common carotid artery was quickly isolated, embedded in OCT 
compound (Tissue-Tek, Sakura, Japan), and snap-frozen in liquid nitrogen. 20 
µm cryosections of both the LSS and the OSS segment were cut and mounted on 
1mm PALM pen-membrane slides. Next, the sections were fixed for 30 seconds 
in 70% ethanol, stained with hematoxylin for 3 minutes,  were rinsed with water 
and dehydrated by several rinses in 100% ethanol. All solutions used during the 
staining procedure were treated with DEPC.
Laser microdissection and RNA purification
To avoid interference by medial or adventitial structures, we exclusively isolated 
the neointima by Laser Microdissection and Pressure Catapulting (LMPC) using 
the PALM Microlaser system (Carl Zeiss Micro-Imaging, Germany). Isolated 
neointimas were dissolved immediately in lysis buffer (Qiagen, Germany) and 
stored at –80 °C for subsequent RNA purification. RNA was purified using 
the RNeasy Micro kit with DNase treatment (Qiagen, Germany) according 
the manufacturer’s protocol, except that 20 ng of 16S/23S bacterial ribosomal 
RNA (Roche Applied Science, Germany) was used as carrier and an additional 
elution was performed in the final step to maximize RNA yield. RNA eluted 
with RNase free water was vacuum evaporated for immediate amplification and 
cDNA generation.
Amplification and labeling of purified RNA samples
Quality of the freshly purified RNA was assayed using the BioAnalyzer 2100 in 
combination with the RNA 6000 Pico chip (Agilent Technologies, USA). When 
intact 18S/28S ribosomal RNA peaks were evident, the sample was considered 
acceptable for further processing. Amplification and cDNA labeling with biotin 
was accomplished using the Ovation RNA Amplification System V2 and FL-
Ovation cDNA Biotin Module V2 respectively according to the manufacturers 
protocols (Nugen Technologies Inc, San Carlos, California, USA). Efficiency of 
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the amplification was assayed quantitatively by 260/280nm estimation of cDNA 
concentration, where a total yield of at least 4.85 µg cDNA was deemed sufficient 
for specific amplification of the RNA template. In order to prevent technical 
induction of differences, the amplification of the samples was performed in two 
randomly composed groups of all samples.
Hybridization of biotin labeled cDNA samples
4 groups were analyzed, which represent two plaque locations (LLS and OSS) 
at 6 and 9 weeks after cast placement. Each group consisted of 6 arrays. All 
samples were hybridized to the arrays in a single batch. Biotin labeled cDNA 
samples were combined with hybridization cocktail including DMSO according 
to the manufacturer’s protocol (Nugen Technologies Inc, San Carlos, California, 
USA) and hybridized to GeneChip Mouse Genome 430 2.0 arrays for 18 hours 
(Affymetrix Inc, Santa Clara, California, USA). Post-hybridization washing, 
scanning and image analysis were performed according to the manufacturer’s 
protocols (Affymetrix Inc, Santa Clara, California, USA). All arrays were run as a 
single batch, in order to prevent batch-effects.
Analysis of microarray expression data
All analyses were performed using BRB-ArrayTools developed by Dr. Richard 
Simon and BRB-ArrayTools Development Team3 (http://linus.nci.nih.gov/
BRB-ArrayTools.html). Raw expression data was imported and normalized using 
the GC Robust Multi-array Averaging (gcRMA) method4. Next, the data was 
filtered such that if a probe set expression values differed at least 1.5-fold from 
the median in at least 20% of the arrays, they were kept for analysis. The overall 
difference between the two groups was visualized by multidimensional scaling 
analysis. This is a method to graphically display high-dimensional data in three 
dimensions. Samples with similar gene expression profiles will lie close together 
in the three-dimensional space to form a cluster. 
Following multidimensional scaling, lists of differentially expressed genes were 
calculated using a multivariate permutation test, to provide a false-discovery rate of 
<10% with 95% confidence (BRB array Tools, class comparison). The multivariate 
test is fully non-parametric and therefore does not require the assumption of 
Gaussian distribution of the data.
Also, instead of only looking at differentially expressed genes it may be very 
interesting to determine how genes between the two locations interact as 
parts of pathways or gene networks. Therefore, we also performed analysis of 
our data using Ingenuity Pathway Analysis (Ingenuity Systems, Inc, Redwood 
City, California, USA). Ingenuity Pathway Analysis (IPA) allows researchers to 
construct knowledge-based structural networks of expression data in the context 
of known functional interrelationships of different genes. 
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Histological validation
8 µm cryosections were cut and stained for the markers bassoon (Synaptic 
Systems, Germany), tyroxine hydroxylase and dopamine beta hydroxylase (both, 
Santa Cruz Biotechnology Inc., USA). Non-relevant rabbit immunoglobulins 
were used for control stainings.
Results & Discussion
In this study we performed genetic analysis by whole-genome microarrays on 
atherosclerotic plaques. We compared expression profiles at 6 and 9 weeks after 
surgical placement of a shear stress modifier, which induces a low shear stress 
and an oscillatory shear stress segment in a single arterial segment. The former 
will develop into a plaque with an unstable phenotype at 9 weeks, whereas the 
latter will become stable at that time point. We search for differential expression 
of genes between the segments at the two different time points and between the 
segments at one time point (Table 1).
Surprisingly, despite technical success of the experiment (see Table 2 for results) we 
did not identify differentially expressed genes within the following comparisons: 
LSS 6 weeks vs. LSS 9 weeks, OSS 6 weeks vs. OSS 9 weeks and LSS 9 weeks vs. 
OSS 9 weeks. Maybe the differentiation into the two plaque phenotypes occurs 
in an earlier phase of plaque development, and therefore could not be detected 
in this study. Another possible explanation is that the genetic differences are 
too small to be detected by the techniques we performed. This might be due to 
the very small amounts of RNA isolated by the laser microdissection, for which 
strong amplification is needed. This induces noise into the data, which might 
obscure delicate differences. 
On the other hand, the genome-wide expression patterns between the LSS and 
P
la
qu
e 
lo
ca
tio
n
Time point
6 weeks
os
ci
lla
to
ry
 s
he
ar
 s
tr
es
s
lo
w
 s
he
ar
 s
tr
es
s
9 weeks
Table 1. Performed comparisons with the expression data.
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OSS segments after 6 weeks of plaque development did show large differences, 
which might underlie the distinct differences found in plaque morphology after 9 
weeks of cast placement. Since it is impossible to see from the raw expression data 
if the samples within a group are comparable, the data is graphically represented. 
The result is shown in the multidimensional scaling plot (Figure 1). In this image 
shows each group (LSS or OSS) is color-coded and each dot represents the data 
of a single sample. Our results show that all six samples from each group nicely 
cluster together at opposite end of the axis, evidencing large differences between 
the groups and similarity within each group. This is an important step, because it 
shows possible sample effects (e.g. due to technical failure or biological variation), 
which may obscure further analysis prior to statistical processing of the expression 
data. 
After performing the multivariate test we found 2329 probe-sets to be differentially 
expressed between the LSS and the OSS plaque segments at 6 weeks, with a 
minimum 2-fold difference. Of these, the majority was overexpressed in the OSS 
segment (2225 probe-sets), many of these genes were very weakly expressed in the 
LSS segment. This resulted in huge fold differences between these segments. In 
Table 3, we listed the probe-sets that differed more than 50-fold.
When these differentially expressed genes were further analyzed by visual 
examination, by gene ontology analysis and by Ingenuity networks analysis, 
curiously enough we did not find any clear vascular or immunological pathways in 
A
Group ng/ul A260 260/280 260/230 
6wk LSS 214,32 6,49 1,93 2,41
6wk OSS 227,87 6,91 1,92 2,40
9wk LSS 221,10 6,70 1,92 2,37
9wk OSS 212,13 6,43 1,92 2,38
B .
%Present GAPDH 5’ GAPDH 3’ GAPDH 3’ 5’ ratio
65,48 1027,89 1682,40 1,69
Table 2. Average quality control data of samples pre and post-hybridization.
A. Result of quality control of RNA yield following linear amplification with the Ovation RNA Amplification 
System V2 and FL-Ovation cDNA Biotin Module V2 (Nugen Technologies Inc, San Carlos, California, 
USA). Average yield in each group was equal. The high 260/280 and 260/230 ratios show that the 
solutions are free contaminants. LSS=low shear stress, OSS=oscillatory shear stress.
B. Post hybridization quality data show good % present (over 50%) and good 3’ 5’ ratio’s (< 3).
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this data. This is unexpected since we already know from histological and qPCR 
analysis that there are differences in the expression of several factors including 
fractalkine5. Moreover, most of the differentially expressed genes were in some way 
related to neurological pathways and mechanisms. This also is difficult to explain, 
since neuronal growth into lesions has not been described before. For example, 
one of the strongly expressed genes links to the neuronal protein bassoon. This is a 
zinc-finger CAG/glutamine-repeat protein selectively localized at the active zone 
of presynaptic nerve terminals6. It’s a structural component of the neuron, which 
to as far as our knowledge has never been described in non-neuronal structures 
and as such a strange find in our data. We stained for bassoon in sections, where 
Figure 1: Multidimensional Scaling plot of all samples (n=12) at 6 weeks. 
Multidimensional scaling aims to visualize the total variation between all the genes in three main compo-
nents along three axes, which contain the first three principal components of the data set. Each sample 
is represented as a single point. If all the dots are scattered across the 3D-space represented by the 
axes, large variation between the samples exists. If samples are clustered together at a single location 
along the axes, they are very similar. If clustered dots have the same colors, this depicts they belong to 
the same experimental group. The two groups of samples clearly differentiate from each other along one 
of the axes, which represents the large differences between the groups (especially since the first principal 
component already describes the separation) as well as the reproducibility within the groups.  
Blue: OSS samples, Red: LSS samples.
124
Chapter 6  |  Gene Expression of Unstable Plaque
Figure 2: Immunohistological staining. 
A: left panel shows 200x image of atherosclerotic plaque after bassoon (red) and SMC alpha-actin 
(green) double staining. Nuclei were stained with DAPI (blue). Right panel shows 1000x magnification. 
There is clear intracellular staining of bassoon in an α-actin positive SMC. The left panel shows many 
bassoon positive cells without α-actin positivity, on morphological grounds most probably SMC as well, 
since double staining with CD68 (macrophage marker) was negative (data not shown). B: dopamine 
beta hydroxylase staining of atherosclerotic plaque, mouse brain and brain magnification (left to right). 
C: Tyrosine hydroxylase staining staining of atherosclerotic plaque, mouse brain and brain magnification 
(left to right)
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tissue expression was very limited. Morphologically we did not stain structures 
resembling neuronal origin. The only positive signal was obtained from a part of 
the plaque smooth muscle cells, which showed nice intracellular staining (Figure 
2). 
Next, we used Ingenuity Pathway Analysis to overlay our gene lists with functional 
data. One of the pathways that is almost fully expressed in these analysis is the 
phox2a pathway (Figure 3). Phox2a is a transcription factor that acts early in 
development to help promote the formation of neurons and regulate neuron 
differentiation7. It also regulates the expression of tyrosine hydroxylase and 
dopamine beta-hydroxylase, two catecholaminergic biosynthetic enzymes essential 
for the differentiation and maintenance of the noradrenergic neurotransmitter 
phenotype. We tried to immunostain some of the enzymes from this pathway in 
mouse sections from the same location and time point. The genes encoding these 
enzymes were among the most highly expressed genes on our arrays. Notably, we 
were unable to show clear positive staining for the following markers: dopamine 
beta-hydroxylase (DBH), tyrosine hydroxylase (TH) and DOPA decarboxylase 
(DDC) (Figure 2). The lack of positive staining for the proteins encoded by these 
genes indicate that high RNA expression is not matched by protein expression 
in atherosclerotic plaque, casting doubts on the significance of the findings by 
microarray. 
In general, we can conclude that the relevance of the findings above for the 
development of atherosclerosis is unknown and that these data are inconclusive as 
such. Since we use such small quantities of RNA to start out with, there is a risk of 
inducing variations due to technical issues. On the other hand, we processed our 
samples in combined batches containing samples of each group. And since the 
samples from the 6 weeks groups are very similar in respect to each other (Figure 
1), this evidences that we are indeed facing true effects of the biology and ruling 
out a technical result. Hypothetically, these data give handles for some possible 
new insights into plaque destabilization. With the emerging field of neuro-
immunology8, 9, one could hypothesize that a neuronal control of the atherosclerotic 
plaque may emerge during development. It is known that effector nerve endings 
in inflamed tissues may alter the expression of pro and anti-inflammatory 
cytokines8. The role of this mechanism in atherosclerosis is still elusive, but is very 
interesting with respect to the occurrence of atherosclerotic events with a circadian 
rhythm10, or during strenuous exercise (high catecholamine expression)11. Before 
such hypotheses based on these data can be justified, the experiments should be 
repeated. This is needed because technological developments have resulted into 
superior techniques to those used in these studies, allowing the collection of more 
reliable data. Furthermore, hypotheses mentioned above should be supported by 
conclusive validation experiments, which are currently lacking.
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The mechanisms behind the development of atherosclerotic plaques and their 
transition to clinically significant lesions are currently not fully clear. It is of 
essential importance to gain knowledge on this matter, in order to develop better 
diagnostic and therapeutic strategies for this disease. Grossly, the studies presented 
in this thesis encompass two main issues in understanding atherosclerosis. The 
first chapters cover the spatial heterogeneity of atherosclerotic lesions. The second 
part describes studies of the inflammatory mechanisms that take place during 
disease development. Both will be discussed consecutively, followed by a vision 
for future experiments.
Plaque heterogeneity 
One of the main issues is that developing lesions are morphologically 
heterogeneous when assessed longitudinally. A single plaque may have multiple 
appearances depending on which segment is examined. This heterogeneity is not 
just a phenotypical feature; it has important clinical consequences as well. It has 
been shown that most plaque ruptures occur in the proximal plaque segment1, 2. 
Since it is currently impossible to accurately study natural history in patients, 
researchers often turn to animal experiments to test their hypotheses. In this 
thesis, both rabbits and mice have been used, and results in both models do not 
always correspond. In chapter 2 of this thesis we showed that there is a correlation 
between the level of shear stress and the histological qualities of the plaque in 
experimental atherosclerosis in rabbits. We showed that matrix degrading 
gelatinolytic activity was highest in the upstream segment and colocalized with 
a subgroup of macrophages and smooth muscle cells, which were associated with 
oxidized LDL. 
Following the above study, we further assessed the heterogeneity of atherosclerotic 
plaques in a mouse model in which the development of atherosclerosis is directly 
coupled to differences in shear stress (chapter 3). In these animals, atherosclerotic 
lesions with characteristics of unstable plaques develop in a segment primed by low 
shear stress, resembling the preferential location for human plaque development. 
In just over half the number of animals studied we found evidence of plaque 
disruption, mainly intraplaque hemorrhage. All disruptions were located in the 
upstream part of the lesion, resembling findings in human.  With respect to our 
findings in rabbits, we were unable to obtain similar results. In rabbits macrophages 
were mostly present in the upstream part of the plaques, whereas in mice the 
macrophages were equally distributed.  Nevertheless, the immunological activity 
of macrophages in mice was strongly focussed in the upstream segment, something 
we did not test for in rabbits. Gelatinolytic activity in mouse plaques was most 
prominent in the downstream segment, which contradicts the previous results in 
rabbits. A possible explanation for this discrepancy may be the big difference in 
approach of creating atherosclerosis in each model. Atherosclerosis in rabbits can 
only develop with a combination of balloon endothelial denudation and a high 
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cholesterol diet. The former removes the endothelial cells from the artery wall, 
removing the natural barrier between blood and vascular wall, allowing lipids and 
inflammatory cells to enter the arterial wall. The endothelial denudation creates 
a physically altered endothelial barrier, whereas in mice the plaque development 
endothelial dysfunction is based on an accepted pathophysiological mechanism 
of altered shear stress. In that sense, the rabbit is a more extreme model of human 
atherosclerotic disease. 
There has not been much research studying the mechanisms behind intraplaque 
heterogeneity, though many papers describe the non-uniform appearance of 
lesions. Recently, work has been published describing the predominant upstream 
localization of plaque ruptures in humans, though the strong upstream localization 
seems to be strongest in the left anterior descending coronary artery (LAD), 
whereas in the right coronary artery a more equal distribution of ruptures is 
seen1, 2. Currently, the PREDICTION trial is ongoing, prospectively monitoring 
coronary segments of low shear stress and expansive remodeling to see if these 
regions show rapid progression of atherosclerosis and eventually plaque rupture. 
Ideally, the results of this study may provide anatomical plaque features, used to 
determine high-risk lesions. This might lead to interventions in a pre-rupture 
state, reducing the occurrence of acute coronary events.
With the recent development and improvement of micro-imaging techniques, 
such as micro-CT3 and micro-MRI4-6, opportunities arrive to downscale 
the experimental concept of the rabbit study to smaller animal models better 
representing the human situation. Also, with the development of high resolution 
imaging techniques, the door is open to characterize histological and functional 
characteristics of a plaque without the need to examine the tissues under a 
microscope. Much effort is currently put into developing molecular imaging 
techniques as well as improving existing imaging techniques to detect specific 
plaque components. The first will employ contrast agents labelled with a specific 
protein that will accumulate in the cell or structure under investigation, enabling 
detection of heterogeneity7, 8. A second approach is to use common imaging 
modalities like CT, MRI and IVUS and optimize imaging protocols to try to 
predict plaque composition. These techniques by themselves will not be able to 
show details on a cellular level, but for that matter they may be combined with 
molecular imaging techniques.  Another advantage of both these approaches 
is that they may be performed repeatedly over time, giving more insight in the 
natural history of plaque development. 
Inflammatory response
In chapter 4 we describe the differential expression of chemokines during the 
development of atherosclerosis induced by two different patterns of shear stress. 
We found differences both in the early and late phases of development, reflecting a 
continuously changing immunological environment. The morphological qualities 
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of lesions induced by either low or oscillatory shear stress are partially an effect of 
the differential expression of CXCL10 (IP-10) and CX3CL1 (fractalkine). 
CXCL10 is a chemokine expressed in low levels in immune structures like lymph 
nodes, but can be highly expressed by monocytes, endothelial cells and SMC 
after stimulation with the pro-inflammatory cytokine IFN-gamma. The receptor 
for CXCL10, CXCR3, is known to be primarily expressed on activated Th1 
cells, which is considered the key Tcell in atherosclerosis. It has been shown that 
CXCL10 is highly expressed in atherosclerotic plaques in humans, and that loss 
of function studies in mice resulted in decreased atherosclerosis. In our studies 
CXCL10 was shown to be primarily present in the early phases of unstable 
plaque development in the low shear stress segment. Besides, we’ve shown that 
inhibition of CXCL10 during it’s highest expression result in smaller and more 
stable lesions. Finally we found that a more stable lesion phenotype correlates 
with lower levels of CXCL10 in carotid plaques in humans. Since CXCL10 is 
considered a Tcell related chemokine, which is highly expressed in our mouse 
model, it is surprising that we find little Tcells in our lesions.  We do find strong 
lymphadenopathy of the lymph nodes draining the carotid artery, suggesting 
clonal expansion of the Tcell population. So far, we did not analyze these lymph 
nodes, but it’s plausible that much of the Tcell effects take place there. 
Monocytes in general are a very multiform inflammatory cell type and known 
to play a key role in atherogenesis. Though monocytes come in a sliding gradient 
of appearances, grossly they are categorized into two main subsets. The first 
develops into inflammatory macrophages (dubbed M1) following vascular 
extravasation. In mice, they highly expresses CCR2 and Ly6C and has low 
expression of CX3CR1 (Ly6Chi, CCR2hi, CX3CR1lo) and is the main circulating 
subset in hypercholesterolemic mice9. The second main subset (M2) gives rise to 
resident type macrophages and dendritic cells and are characterized by a Ly6Clo, 
CCR2lo CX3CR1hi phenotype. In humans similar subsets have been described 
and though dissimilarities are present10, it appears to be a highly evolutionary 
preserved phenomenon. It must be kept in mind though, that results from the 
mouse studies cannot be directly translated to human disease. 
It is thought that this differential expression of chemokine receptors lies at the 
basis of the different phases of disease progression. It was expected that the CCR2-
CCL2 and the CX3CR1-CX3CL1 axes were the differentiating factors in subset 
accumulation into the plaque, determining the fate of plaque development.  A 
lower prevalence of atherosclerotic events was described in humans carrying a 
genetic polymorphism of the CX3CR1 gene, resulting in a loss of function11. 
Possibly this is due to a lower dendritic cell presence in the arterial wall, resulting 
in less immune activation12. Moreover, in our own studies we find differential 
expression of chemokines, further supporting that hypothesis. Fractalkine comes 
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to expression during a later phase in the low shear stress segment, just when the 
plaque destabilizes. This a key step in the disease progression in this model, since 
inactivation of fractalkine with antibodies results in the development of a stable 
phenotype with more collagen and less macrophages. This supports the concept 
that introduction of a different subset of monocyte derived cell to the plaque 
drives its destabilization.
Contradicting this concept, it was shown recently that both M1 and M2 
subsets use the CX3CR1-CX3CL1 axis gaining access to the vessel wall, be it 
in combination with other chemokines, like CCL513. This sheds new light on 
recruitment mechanisms and also may have consequences in the development 
of pharmacological agents to prevent atherosclerosis development. It may be 
necessary to inhibit multiple chemokine axes to achieve the desired effects, which 
may also increase chances of unwanted side effects like increased susceptibility to 
infections.
 
Future directions
The studies presented in this thesis comprise the two main concepts described 
above. Future research should be focussed on combining both concepts into a 
disease mechanism. In order to achieve that, first the immunologic phenotype of 
the macrophages accumulating upstream in our mouse model should be further 
determined, especially with regards to chemokine pathways. The functional 
relevance of the pathways found, should be studies by using specific chemokine 
(receptor) inhibition models based on genetic loss-of-function and/or functional 
inhibition with antibodies or specific peptides.  Once these pathways are 
functionally confirmed, it is necessary to study the kinetics of these macrophages 
by intravital labelling techniques, for example by applying subset specific targeted 
liposomes or micelles in conjunction with high resolution imaging techniques 
like micro-MRI or micro-CT. Also, when using fluorescent labels, intravital 
microscopy can be used. As a first step, kinetics should be studied in multiple mice 
at multiple time points. Later, repeated measures in single mice could be added. 
This approach could also be applied to other atherosclerotic predeliction sites like 
the brachiocephalic artery to rule out model specific mechanisms. 
Another issue that needs to be resolved is the lack of Tcell presence in the lesions 
of the shear stress mediated plaques. For that, the first step would be to analyze 
the components of the draining lymph nodes of the plaques by standard FACS 
techniques, specially focussing on a shift towards a more regulatory Tcell phenotype. 
Also, the plaques should be analyzed at the currently missing time points (2,4,5 
and 7 weeks of cast placement) for presence of Tcells. Although this will probably 
not yield publishable data, it will provide for a much better understanding of the 
model in general, which in turn may direct future experiments.
Finally, when the studies above have been performed and a clear monocyte 
migration mechanism has been resolved, the findings should be translated towards 
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human atherosclerosis, which might be the biggest challenge. Especially since 
the biological safety of applying labelled contrast agents in humans is unclear. It 
will be very difficult to get approval from medical-ethical committees to perform 
those kinds of studies. Until then, human research will be mostly descriptional 
with respect to cellular composition of plaques by using post-mortem or 
surgically obtained specimens. By using blood samples of both symptomatic and 
asymptomatic patients, we may be able to study plaque dynamics on basis of 
derived parameters.
In conclusion, the field of (experimental) atherosclerosis research will be an 
exciting area to operate in for the next decades, hopefully resulting in proper 
diagnostic and therapeutic possibilities for the generations to come. 
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Summary
Atherosclerosis is considered a major clinical problem, which underlies most 
ischemic events of both the heart as well as the brain. From the second decade 
in life onwards, the disease progresses more rapidly. The clinical silence of 
atherosclerosis is often broken between the third and fifth decade, when patients 
present with ischemic complaints of e.g. heart and brain. 
Lipid metabolism and inflammation mutually influence each other yielding 
the complete spectrum of atherosclerotic disease progression. The development 
of atherosclerosis is strongly associated with conditions like hypertension, 
diabetes, and hypercholesterolemia and bad life style habits like smoking and 
lack of physical exercise. They induce an unbeneficial environment for the arterial 
vasculature, enabling the circulating cholesterol-containing lipoproteins to 
invade the vascular wall. The vessel wall starts to produce inflammatory signaling 
molecules like chemokines and adhesion molecules. Subsequently, these attract 
and bind leukocytes to the vascular wall and enhance the inflammatory process, 
resulting in atherosclerotic disease progression.
Although the classical risk factors of atherosclerosis are of systemic nature, it has 
long been observed that plaques are not evenly distributed along the arterial tree. 
In fact, atherosclerotic lesions appear at specific predilection sites. These sites are 
at or near side branches or bifurcations, where blood flow is non-uniform, or at 
the lesser curvature of bends, where blood velocity is relatively low. The effect of 
blood flow on the vessel wall is mediated through fluid shear stress, which arises 
from the friction between the flowing blood and endothelial cell layer, the inner 
lining of arteries. It induces a shearing deformation of the endothelial cells, which 
will be sensed and followed by a biological response influencing atherosclerosis 
development. The clinical aspect of atherosclerotic disease progression is not 
merely the slow narrowing of the vascular lumen, resulting in reduced blood flow 
to the downstream tissues. Depending on the plaque morphology, it may rupture 
under the influence of the flowing blood. The freed fatty plaque contents induce 
a sudden thrombotic response, resulting in acute arterial obstruction. It was 
previously that shown plaque morphology is dependent on the shear stress pattern 
the vessel wall was exposed to. Arterial locations exposed to: 1. Low shear stress 
give rise to unstable plaques prone to rupture, 2. High shear stress protects from 
atherosclerosis and 3. Oscillatory shear stress results in stable plaque formation.
So, evidence exists that the shear forces on the endothelial cells influence the 
development of plaque vulnerability. However, the (immunological) mechanisms 
involved in this shear stress mediated vulnerable plaque development are currently 
unclear. In this thesis we aimed to clarify some of the immunological mechanisms 
involved, working towards future therapeutic interventions in treatment and 
prevention of unstable plaque rupture. Since it is very difficult to perform such 
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mechanistic studies in humans, we studied experimental atherosclerosis in two 
specific animal models.
In Chapter 2, we studied the spatial organization of atherosclerotic plaques in 
relation to local variations of shear stress along the vessel wall. By obtaining the 
arterial geometry by intravascular ultrasound of an atherosclerotic plaque created 
in rabbits, we were able to calculate the differences of shear stress along the 
length of the plaque. Next, we superimposed the histological data acquired later 
onto this geometry. By using elaborate image processing software we were able 
to show the spatial relation of histological markers like macrophages, smooth 
muscle cells, lipids, gelatinolytic activity, and oxidized low-density lipoprotein 
in relation to their local shear stress pattern. Results showed a predominant 
upstream localization of macrophages and gelatinase activity. Colocalization 
studies indicated that gelatinase activity was associated with macrophages and 
smooth muscle cells, and that this was caused by subsets of smooth muscle cells 
and macrophages, which were associated with oxidized low-density lipoprotein 
accumulation.
We concluded that localization of a vulnerable plaque phenotype is probably due 
to an accumulation of oxidized low-density lipoprotein, which activates/induces 
subsets of smooth muscle cells and macrophages to gelatinase production, which 
results in plaque degradation and destabilization of the plaque.
Chapter 3 describes further studies of the spatial organization of plaques, this 
time in plaques induced by a standardized shear stress modifying device (cast) in 
a mouse model of atherosclerosis. We focused on plaques exposed to low shear 
stress, which is known to acquire characteristics of vulnerable plaque. We found 
evidence of plaque disruption (e.g. intraplaque hemorrhage), but only in the 
upstream segment of the lesions, accompanied by increased macrophage activation 
compared to the downstream segment. The upstream localization of disruptions 
is in accordance with findings in humans. We concluded that the vulnerability 
of atherosclerotic plaque induced by a low shear stress flow pattern is located 
predominantly in the upstream lesion segment. This is associated with activation 
of macrophages and relatively low collagen content, but partly dissociated from 
gelatinase activity.
Following these studies of descriptive nature, we next focused on the 
immunological mechanisms that underlie the findings described above. Therefore 
we studied the expression and function of multiple chemokines during different 
stages of atherosclerotic plaque development in our mouse model using the shear 
stress modifying cast. In chapter 4 we first determined which of the chemokines 
previously mentioned to be critical in disease development are expressed in our 
lesions. We found clear differences between the plaques induced by low and 
oscillatory shear stress. We also found differences within the segments over time. 
So plaque dynamics are both shear stress and time related. We found for example 
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that MCP-1, a key chemokine involved in monocyte recruitment, was expressed 
highest during the early phases of plaque development in both low and oscillatory 
shear stress segments, but expression was much lower at later time point when 
low shear stress lesions destabilized. Fractalkine, another monocyte recruiting 
chemokine, was selectively expressed in the low shear stress segment during the 
destabilization. Since this was such a striking finding, we performed fractalkine 
inhibition studies, which resulted in much more stable lesions, characterized by an 
increase in collagen and a decrease in macrophages. We concluded that different 
shear stress fields yield different plaque compositions associated with different 
responses in chemokine expression. We also concluded that low shear stress 
induces the development of larger lesions of which the composition resembles 
lesions in humans with a less “stable” phenotype and that fractalkine appears to 
be crucial in the development of the distinct plaque phenotype that is induced by 
LSS. 
A second chemokine that was selectively expressed in low shear stress induced 
lesions was CXCL10. This particular chemokine was studied in mice in a similar 
way as fractalkine (chapter 5). By inhibiting CXCL10, which is expressed earlier 
in the plaque development compared to fractalkine, we found that plaques were 
similar in size, but with much less macrophage activation and more collagen 
content. This resulted in plaque morphology with a more stable phenotype. We 
found that there is an association between the plaque concentration of CXCL10 
and a more atheromatous phenotype in human carotid artery specimens obtained 
during endarterectomy. Thus we concluded that CXCL10 is a key chemokine 
in atherosclerosis and that a functional relationship was shown in mice, whereas 
clues for a similar relationship in humans were found. 
Since the molecular pathways underlying the inflammatory response in 
artherosclerotic plaque development are extremely complex, we tried to gain 
further insight by using whole-genome microarrays (chapter 6). By laser capture 
microdissection, we solely obtained plaque tissue with endothelial cells, excluding 
the muscular arterial wall and its adjacent adventitial structures. This was done to 
get a clearer signal from mechanisms inside the plaque itself. The extracted RNA 
from the captured lesions was amplified and run on microarrays. The results were 
unexpected since no clear vascular or immunological pathways were identified 
during post-analysis. Moreover, we did find some highly expressed neuronal 
proteins to be present, but only one of these could be detected by immunostaining. 
The relevance of these findings for the development of atherosclerosis is unknown 
and at present these data do not substantiate any firm conclusions. In the 
light of (technical) advancements in both small quantity RNA processing and 
bioinformatic analysis methodology, the study should be repeated in order to 
draw any conclusions.
In chapter 7 the results of this research project is discussed in a broader perspective 
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with regard to atherosclerosis development and suggestions for future directions 
are discussed.
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Atherosclerose, in de volksmond aderverkalking, is een klinisch belangrijk 
probleem, wat ten grondslag ligt aan ischemische aantasting van zowel het hart 
als de hersenen. Vanaf de tweede decade van het leven, ontwikkeld de ziekte zich 
steeds sneller. De klinische stilte ervan wordt vaak doorbroken vanaf middelbare 
leeftijd, wanneer patiënten klachten krijgen als gevolg van zuurstof tekort in de 
hartspier en/of het brein. 
Vetstofwisseling en ontsteking beïnvloeden elkaar wederzijds, waarbij het hele 
spectrum van het ziektebeeld tot uiting komt. Progressie van het ziektebeeld 
is sterk geassocieerd met hoge bloeddruk, diabetes, een verhoogd cholesterol 
en slechte leefgewoontes zoals roken en gebrek aan beweging. Deze factoren 
faciliteren een ongunstig milieu voor de arteriële vaatsysteem waarin cholesterol 
bevattende lipoproteïnen  zich in de vaatwand kunnen nestelen. Dit stimuleert 
de vaatwand tot productie van ontstekingsgebonden signaal moleculen, zoals 
chemokines en adhesie moleculen. Vervolgens trekken deze signaal moleculen 
witte bloedlichamen aan welke het ontstekingsproces verder stimuleren, wat leidt 
tot progressie van de aderverkalking. 
Ondanks dat de risicofactoren voor atherosclerose over het gehele lichaam hun 
effect hebben, is het al lang bekend dat aderverkalking niet gelijkmatig is verdeeld 
over de vaatboom. In tegenstelling juist, er zijn voorkeurslocaties te beschrijven. 
Deze locaties bevinden zich bij aftakkingen of splitsingen van bloedvaten (daar 
waar de bloedstroom niet uniform is), of in binnenbochten (waar de bloedstroom 
relatief laag is). Het effect van de bloedstroom op de vaatwand wordt gestuurd 
door de shear stress (afschuifspanning), welke voortkomt uit de wrijving tussen 
het stromende bloed en de bedekkende cellaag (het endotheel) van het bloedvat. 
De shear stress zorgt voor een vervorming van de endotheelcellen, welke wordt 
waargenomen door de cel, wat weer leidt tot een biologische respons welke de 
aderverkalking beïnvloedt.
Het klinische aspect van atherosclerose is niet slechts het langzaam smaller 
worden van de vaatdoorgang (lumen), wat leidt tot verminderde bloedstroom naar 
de weefsels achter de vernauwing. Afhankelijk van de opbouw en samenstelling 
van de atherosclerotische plaque, kan deze scheuren onder invloed van het 
stromende bloed. Der vettige plaque inhoud komt dan in contact met het bloed, 
wat resulteert in een acute stollingreactie gevolgd door plotse verstopping van het 
bloedvat. Het is bekend dat de samenstelling van de plaque afhankelijk is van de 
soort shear stress die op de vaatwand wordt uitgeoefend. 1. Lage shear stress geeft 
instabiele plaques die kunnen scheuren. 2. Hoge shear stress beschermt tegen 
aderverkalking. 3. Oscillatoire shear stress resulteert in stabiele plaque vorming. 
Er is dus wetenschappelijk bewijs dat afschuifkrachten op het endotheel de 
plaque stabiliteit beïnvloedt. De (immunologische) mechanismen die hieraan 
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ten grondslag liggen, zijn echter nog onduidelijk. In dit proefschrift hebben we 
gepoogd enkele van deze immunologische mechanismen verder te ontrafelen, om 
toekomstige therapeutische interventies en behandeling van instabiele plaques 
mogelijk te maken. Om dat het zeer moeilijk is om deze mechanismen in mensen 
te onderzoeken, hebben we hiervoor twee verschillende proefdiermodellen 
gebruikt.
In hoofdstuk 2, hebben we de spatiële organisatie van plaques bestudeerd in 
relatie met de locale variaties in shear stress over de vaatwand. Met behulp van 
intravsaculaire ultrageluid (IVUS) opnames werd de geometrie van in konijnen 
opgewekte atherosclerotische plaques verkregen. Op basis hiervan  werd de 
verdeling van shear stress berekend. Vervolgens werd de histologische data van 
de plaques hier overheen gelegd. Met behulp van uitgebreide image processing 
software konden we spatiële relatie tussen histologische markers van macrofagen, 
gladde spiercellen, lipiden, gelatinolytische activiteit en geoxideerd low-
density lipoproteine (oxLDL) vergelijken met de locaal aanwezige shear stress 
patronen. De resultaten toonde een voorkeur voor stroom opwaartse ophoping 
van macrofagen en gelatinolytische activiteit. Colocalisatie studies toonde dat 
gelatinase activiteit geassocieerd was met macrofagen en gladde spiercellen en dat 
dit werd veroorzaakt door een subgroep van deze cellen welke geassocieerd was 
met ophoping van oxLDL. We concludeerden dat de lokalisatie van het instabiele 
plaque fenotype waarschijnlijk het gevolg is van een ophoping van oxLDL, wat 
een subgroep van gladde spiercellen en macrofagen activeert tot de productie van 
gelatinase, wat resulteert in de afbraak en destabilisatie van de plaque.
In hoofdstuk 3 wordt de spatiële organisatie van plaques verder beschreven, dit 
maal in plaques die zijn opgewekt met behulp van een gestandaardiseerde shear 
stress veranderende cilinder (cast), in een muis model voor atherosclerose. We 
richtten ons op de plaque geïnduceerd onder lage shear stress, waarvan bekend is 
dat ze kenmerken van een instabiele plaque kunnen hebben. We vonden bewijs 
voor verstoring van de plaque (bijvoorbeeld intraplaque bloedingen), maar alleen 
in het stroomopwaartse deel. Dit ging gepaard met verhoogde aanwezigheid van 
macrofagen vergeleken met het stroomafwaartse deel. Deze stroomoopwaartse 
neiging tot disruptie is in overeenstemming met bevindingen in mensen. We 
hebben geconcludeerd dat neiging tot instabiliteit van door lage shear stress 
geïnduceerde plaques zich vooral bevind in de stroomopwaartse delen van de 
plaque. Dit is geassocieerd met activatie van macrofagen en een relatief lage 
hoeveelheid collageen, echter zonder verhoging van de gelatinase activiteit.
Na deze twee beschrijvende studies hebben we ons gefocust op de onderliggende 
immunologische mechanismen. Hiervoor hebben we de expressie en functie van 
enkele chemokines gedurende verschillende tijdstippen van atherosclerotische 
plaque ontwikkeling bestudeerd in het muis model met behulp van de shear stress 
beïnvloedende cast. In hoofdstuk4 hebben we eerst bepaald welke van de eerder 
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voor atherosclerose relevante beschreven chemokines tot expressie komen in ons 
model. We vonden opvallende verschillen tussen de plaque segmenten blootgesteld 
aan lage en oscillatoire shear stress. Daarnaast was er ook een duidelijk verschil 
in expressie over de tijd. Dus de plaque dynamiek wordt beïnvloed door zowel de 
locatie als het tijdstip. We beschrijven bijvoorbeeld dat het chemokine MCP-1, 
welke belangrijk is bij het aantrekken van monocyten, het hoogste is  in de vroege 
fases van plaque ontwikkeling in zowel gebieden van lage als van oscillatoire 
shear stress, maar dat de expressie later veel lager is als wanneer het lage shear 
stress segment instabiele kenmerken toont. Fractalkine, een chemokine wat ook 
monocyten aantrekt, daarentegen was specifiek hoog in expressie in het lage 
shear stress segment gedurende plaque destabilisatie. Omdat dit zo’n opvallende 
bevinding was, hebben we vervolgens fractalkine remmingsexperimenten 
verricht. Dit resulteerde in veel stabielere plaques, gekenmerkt door hogere 
aanwezigheid van collageen en lagere aantallen macrofagen. We concludeerde dat 
verschillende shear stress profielen leiden tot morfologisch verschillende plaques 
wat wordt veroorzaakt door verschillen in chemokine expressie. Daarnaast werd 
geconcludeerd dat lage shear stress zorgt voor grotere plaques met instabiele 
kenmerken en dat fractalkine hierin een sleutelrol speelt.
Een tweede chemokine dat specifiek tot expressie kwam in lage shear stress plaques 
was CXCL10. Dit specifieke chemokine werd op eenzelfde manier bestudeerd als 
fractalkine (hoofdstuk 5). Door remming van CXCL10, wat eerder tot expressie 
komt in vergelijking met fractalkine, vonden we dat de plaquegrootte niet 
veranderde, maar dat de hoeveelheid collageen toename en de macrofaag activatie 
daalde. Dit resulteert in stabielere plaques. Daarnaast beschrijven we dat er in 
atherosclerotisch materiaal, verkregen tijdens menselijke halsslagader operaties, 
een associatie is tussen de hoeveelheid CXCL10 in de plaque en een meer 
atheromateuze plaque morfologie. We hebben geconcludeerd dat CXCL10 een 
sleutel chemokine is de ontwikkeling van atherosclerose en dat er een functionele 
relatie is aangetoond in muizen en aanwijzingen voor een gelijk mechanisme in 
mensen.
Omdat de moleculaire mechanismen die ten grondslag liggen aan de 
ontstekingsreactie in atherosclerose extreem complex zijn, hebben we met 
behulp van whole genome microarrays getracht hierin meer inzicht te verkrijgen 
(hoofdstuk 6). Met behulp van laser capture microdissectie, hebben we specifiek 
het plaque weefsel geïsoleerd om verstoring van de adventitia en spiercellaag 
van de vaatwand te voorkomen. Het RNA wat hieruit werd verkregen werd 
vermenigvuldigd en gemeten op microarrays. De resultaten waren onverwacht 
omdat er geen duidelijk vasculair of immunologisch profiel naar boven kwam 
tijdens de analyse van metingen. Er waren een aantal neuronale eiwitten die sterk 
vertegenwoordigd waren, echter geen enkele daarvan kon histologisch worden 
bevestigd in de weefsels. De relevantie van deze bevindingen in het kader van 
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atherosclerose zijn nog onduidelijk en niet voldoende voor enige conclusies. In 
het kader van (technische) vooruitgang in het verwerken van zeer minuscule 
hoeveelheden RNA en bioinformatica analyses die er op volgen, moet deze 
studies worden herhaald indien we duidelijke conclusies willen trekken. 
In hoofdstuk 7 worden de bevindingen van dit onderzoeksproject in een breder 
perspectief bediscussieerd met betrekking op ontwikkeling van atherosclerose en 
worden suggesties gedaan voor toekomstig onderzoek.
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Als laatste misschien wel het meest gelezen onderdeel van het proefschrift; het 
dankwoord. Vanzelfsprekend doe je een AIO-project niet in je eentje. Ik denk ook 
niet dat het mogelijk zou zijn en je moet het ook niet willen. Alle samenwerking 
is een van de meest waardevolle onderdelen van het hele proces. Vandaar dat 
een woord van dank dan ook het minste is wat ik kan doen om de mensen te 
erkennen die me hebben bijgestaan. Het risico bestaat natuurlijk altijd dat je 
iemand vergeet, gelukkig weten degenen die dank toekomt dat ook zonder een 
paar regels hieronder.
Professor Krams, beste Rob. Dank je wel voor de mogelijkheden die je me hebt 
geboden om dit project uit te voeren. Ik denk dat je een zeer goede wetenschapper 
bent. Je creativiteit en originaliteit zie ik als benijdenswaardige eigenschappen en 
ben dan ook blij dat je mijn promotor wil zijn. Ook al was de samenwerking na 
je vertrek uit Rotterdam soms moeizaam, indien nodig kon ik toch een beroep op 
je doen. Ik heb de gehele ervaring als zeer leerzaam en uitdagend ervaren, dank 
daarvoor.
Professor Van der Steen, beste Ton. Ondanks het feit dat ons beider werk zich in 
de uitersten van het spectrum in atherosclerose onderzoek bevinden, werken we 
toch aan hetzelfde doel. Het is een genoegen om onder je te promoveren. Dank je 
wel voor de geboden ondersteuning, vooral ook in de laatste fase van het project.
Professor Duncker, Professor Grosveld en Professor Pasterkamp dank aan jullie 
allen voor het zitting nemen in de kleine commissie en het lezen en beoordelen 
van mijn proefschrift. Ik ben zeer benieuwd naar jullie commentaren.
Rini de Crom, beste Rini, mijn redder in “verlaten-AIO-nood”.  Mijn dank is 
groot. Voor de benchruimte, een kantoorplek, je laboranten, je organisatie (talent), 
je rust, de financiële ondersteuning. Zo kan ik nog wel even door gaan, maar 
vooral bedankt voor het beschikbaar zijn waneer het nodig was! Ik zou niet weten 
hoe het had moeten gaan als je me niet zo had gesteund. Nogmaals heel veel dank.
Pieter Leenen, beste Pieter. Wat ben jij een aanstekelijk enthousiast persoon. 
Ik heb ècht genoten van alle korte ad hoc- en lange geplande meetings. De 
manier waarop jij in de wetenschap staat is geweldig. Geen gedachte is gek of 
onconventioneel genoeg, maar nooit uit de lucht gegrepen. Dank voor alle steun 
over de afgelopen jaren, zowel wetenschappelijk als persoonlijk. Hopelijk krijg je 
de mogelijkheid om nog wat langer in het atherosclerose veld te blijven werken.
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Alle mensen op de verschillende laboratoria (semi-chronologisch). Luc van 
Damme, dank je voor je hulp bij de 3D histologie studie. Je beloning komt echt 
nog een keer; Feyenoord wordt vast wel weer eens kampioen. Caroline Cheng; ik 
heb je niet altijd begrepen, wel altijd zeer gewaardeerd. Ik heb grote bewondering 
hoe jij door je wetenschappelijke carrière gaat. Veel succes.  Dennie, dank je voor 
al je antwoorden en hulp op het lab. Veel succes nu met je eigen AIO project. 
Hang in there, de vruchten aan het eind zijn zoet. Rien, ik vind het jammer dat 
we elkaar pas op het einde van mijn lab-tijd hebben leren kennen. Je kennis is 
ongekend, je organisatie methoden trouwens ook. Teus, bedankt voor je analyses 
van mijn serum samples. Ik zal proberen om de toevoer aan Zweden kalenders 
voor je veilig te stellen. Adrie/A3, jammer dat onze gezamenlijke inspanningen 
op de FACS niet zijn gehonoreerd, ik had het graag anders gezien. Jon Laman 
dank je voor de vele prikkelende vragen die je me hebt gesteld. Marjan van Meurs 
bedankt voor al jullie hulp bij de kleuringen. Kim, ik zal al je vragen missen. Je 
neemt mijn rol op de afdeling celbiologie al langzaam over. Veel succes daarmee 
(en mail me maar als er toch nog een vraagje overblijft).
Al mijn andere lab collega’s van de afdelingen Celbiologie en Genetica, 
(Experimentele) Cardiologie, Immunologie dank voor de praatjes en de 
inspirerende tijd aan de bench, in de flow-kast of achter de microscoop. Voel je 
zéker aangesproken!
Beste Sonja, het was fijn om dagelijks met je te lunchen. Even de gedachten 
verzetten en na de cappuccino weer opgewekt aan de slag. Ik ben het zeker gaan 
missen.
Beste Mieke, hoofdcoordinator voor mijn promotie plechtigheid, dank je voor al 
het werk dat je voor me hebt gedaan. Het was fijn om iemand te hebben die alle 
vragen over de promotie kon beantwoorden.
Karl, thanks mate for all your support in the micrarray study. Your meticulous 
methods in performing the work were awesome. Also thanks for the nice 
conversations and the movies. Good luck in your scientific carreer.
Thijs, bedankt kerel. Het was fijn om af en toe mijn pieken en dalen met je te delen, 
in de wetenschap dat je precies wist wat ik bedoelde omdat je met dezelfde dingen 
rond liep.  Ik heb onze lunches erg gemist de laatste jaren. Het was bijzonder om 
samen door deze fase heen te gaan. Wij komen er wel. Het was mijn eer om bij 
jou promotie naast je te staan. Nu is het jou beurt. 
Bram, fijn de je mijn paranimf wil zijn. De gesprekken met jou waren een steun 
in zowel de goede als de lastige tijden. Het is fijn om af en toe te kunnen sparren 
met iemand met onderzoekservaring in een ander veld.  Dank daarvoor. We gaan 
snel een tafel in Muiderberg reserveren. In een restaurant bedoel ik dan.
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Heeren reünisten van D.D.A.M.T. Meridies, jullie jarenlang durende hoon over 
het gedoe met muisjes was mooi. Precies wat je van dispuutsleden verwacht. 
Gelukkig proefde ik tussen die hoon genoeg oprechte interesse en steun die zo 
onmisbaar zijn tijdens een promotie traject. Bedankt. Binnenkort een biertje 
doen?
Walter, Franka en Irene, ook jullie mag ik zeker niet vergeten. Jullie positieve blik 
op het leven is inspirerend en was een goede bron van motivatie als het even tegen 
zat. 
Caroline, Stinky, zusje, dank je wel voor je lieve steun en betrokkenheid. Je 
telefoontjes en onze gezamelijke gekkigheid zijn altijd welkom. Het is maar 
goed dat er niet overal camera’s hangen, anders waren we allang samen ergens 
opgesloten. Gelukkig kunnen we ook serieus zijn, en da’s mooi!
Pappa en mamma, Gert Jan en José. Dank je wel voor jullie onvoorwaardelijke 
steun en interesse. Het is moeilijk uit te leggen hoe belangrijk dat tot op de dag 
van vandaag nog is. 
Als laatste natuurlijk Mireille, lief Miepje. Wat hebben we het toch goed samen! 
Het is een genot om iedere dag weer bij je te zijn. Goede dagen worden gekoesterd 
en slechte dagen zijn zo weer vergeten. Deze fase hebben we in ieder geval samen 
tot een goed einde gebracht. We hebben nog een geweldige tijd voor de boeg en 
het is het grootste plezier van mijn leven dat ik dat met jou mag gaan beleven. Ik 
hou van je, dikke kussie!
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Dolf Segers was born on August 28th in Tilburg, The Netherlands. In 1995 
he graduated from HAVO at the Mollerlyceum in Bergen op Zoom. Directly 
following, he participated in a high school exchange programm for one year 
in Lancaster, Califormia, USA. It was there and then he decided to become a 
medical doctor. Upon return he obtained his necessary VWO diploma within the 
same year. 
In 1998, he got admitted to medical school at the Erasmus University Medical 
Center in Rotterdam, after one year of studying Health Sciences at the Maastricht 
University. In 2002 he obtained his medicine masters degree, after finishing his 
master thesis in the department of Experimental Cardiology of the Erasmus 
University Medical Center, which was headed by professor Dirk Duncker. 
This research project was supervised by professor Rob Krams and resulted in a 
position as a PhD candidate in the department of Biomedical Engineering of the 
Thoraxcenter in Rotterdam. During his PhD studies from 2003 until 2009, he 
also finished his internships and obtained the MD degree in 2005. 
Since April 1st 2009, he is a cardiologist-in-training under supervision of dr. 
F.J. ten Cate at the Thoraxcenter of the Erasmus University Medical Center. 
Currently, he is working as a resident at the department of cardiology at the 
Amphia Hospital in Breda, The Netherlands.
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Specific courses offered by COEUR:                                                   Year ECTS
Congenital heart disease 2004 1.5
Atherosclerosis research 2006 1.5
Molecular biology in atherosclerosis and cardiovascular research 2007 1.5
Cardiovascular imaging and diagnostics 2008 1.5
Erasmus MC courses 
Basiscursus Microchirurgie 2005 1.5
Analysis of microarray gene expression data 2007 1.5
Statistiek basis 2007 1.5
Biomedical writing 2007 4
COEUR Research seminars: Year ECTS
Arrythmia Research 2007 0.4
Other courses followed: Year ECTS
Artikel 9, wet op dierproeven 2004 4,5
Dutch Heart Association course Vascular Biology 2005 2.0
Postdoctorale cursus Medische Immunologie 2007 1.5
Symposia and congresses Year ECTS
Dutch Atherosclerosis Society symposium
2004, 2005, 2006, 
2007
2.1
Shear Stress symposium 2006, 2007, 2008 1.8
AHA Scientific Sessions 2006, Chicago, USA 2006 1.5
NVVI voorjaarssymposium 2006, 2007 1.2
AHA Scientific Sessions 2007, Orlando, USA 2007 1.5
Supervision of students Year ECTS
Internship of 4 HLO students (6 months each) 2006-2008 8
Internship of 1 MLO Student (6 months) 2008 2
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